BICMG

Business Information Consulting & Management Group

New Medical Technology Drastically Improves Treatment for Stroke Victims by Scott Willis, Allegra Craver, & Leo Tully

Potential stroke victims in Central New York and their families can rest a little easier thanks to the findings of a new study that has broadened the timeframe for stroke treatment. The study determined patients can seek treatment for up to 24 hours following a stroke. Thanks to a new technology called RAPID, doctors can scan the brain for salvageable brain tissue in minutes, a process that previously took up to 40 minutes and was unreliable. Interventional Neurologist at Upstate Medical Center Hesham Masoud says the combination of the bigger window and faster treatment is equivalent to a defibrillator for heart attacks or penicillin for infections.

 “I think the broader implication for this trial is for those centers that will not transfer patients to our hospitals for thrombectomy, meaning to get out the clot, because they think, ‘Oh well. This happened six or seven, eight hours ago, so that’s beyond the window, so I won’t do this life saving transfer.’”

Before RAPID, patients had roughly six hours to get from their homes to the hospital and receive treatment. Masoud says this technology will allow one in three patients to go home after having their stroke.

 “This is an opportunity to identify more patients that can benefit from this treatment. In a group where it was thought to be that these patients did not have options, we’re seeing that not only do they have options, but that this is a huge treatment effect.”

While this new window is promising for stroke victims, Kristy Smorol with the American Heart Association says it is still important to come to the hospital as fast as possible after having had a stroke.

“We still want that urgency to be there. We still want people to get to the hospital as soon as they can. If that 24 hour window is helpful, that’s wonderful, but the longer you wait - even if it’s within those 24 hours - the less effective the procedure will be. Every minute counts.”

She advises people to look for drooping in the face, weakness in the arm, and difficulty speaking. If any of these symptoms pervade, call 911 immediately.

 

Source: http://waer.org/post/new-medical-technology-drastically-improves-treatment-stroke-victims

Adhesive Considerations for Direct-Skin Wearable Medical Technologies by Janet Page

biosensor.jpg

In addition to caring for the sick, today’s medical providers are also heavily focused on prevention, patient education, and health and wellness strategies. As part of this newer approach to healthcare, providers are implementing ways to deliver additional care options that are both easily accessible and more affordable. Of these, one of the fastest growing and most widely adopted is wearable medical technologies.

Wearable medical technologies not only provide support for care related to acute and chronic medical conditions, but also for disease prevention and lifestyle choices. They can monitor health, remind patients to take medications, and perform other health-related tasks.

According to eMarketer, the number of U.S. adults that used a wearable medical device in 2015 was 39.5 million, nearly 58 percent more than in 2014. eMarketer says that number will skyrocket to more than 81 million Americans by 2018. Similarly, Global Industry Analysts Inc. predicts the global market for wearable medical devices will reach $4.5 billion by 2020.

Trends in Direct-Skin Wearable Medical Technologies

While the wearable medical technology market is vast—from watches or armbands that monitor fitness activity to specialized gloves that help with mobility and running shoes that reduce potential injury—a significant sector of the market is dedicated to solutions that require adhesion to a user’s skin.

For example, flexible patches that can track user temperature over time is a trending technology. These continuous-temperature, remote-monitoring devices are often used for babies and young children, post-operative patients, cancer patients, and elderly patients. They are typically placed near the user’s armpit, and providers are notified of temperature changes, such as fevers, by way of mobile alerts.

Other trending wearable medical technologies that use adhesives to apply the technology directly to the user’s skin include:

  • Heart-monitoring devices that record a user’s heart rate and rhythm (electrocardiogram activity) for a certain timeframe, generally 24 to 48 hours.
  • Glucose-monitoring devices that are designed as continuous insulin delivery systems, checking and monitoring a user’s blood-glucose levels around-the-clock.
  • TENS (transcutaneous electrical nerve stimulation) electrode therapy devices that use low-voltage electrical current for muscle pain management and relief.

Compared with other application methods, using adhesives to adhere these technologies directly to the skin delivers a multitude of benefits, including:

  • Eliminating the need for bands or other bulky or uncomfortable components to properly affix the technology.
  • Making the technology lighter in overall weight and more convenient and easy to use.
  • Improving data accuracy as the technology is more precisely kept in place.

However, as with all direct-skin applications, the type of adhesive used for these four wearable technology trends (continuous-temperature remote monitoring, heart monitoring, glucose monitoring, and TENS electrodes devices) is imperative to success.

 

Above image courtesy of Mactac. Many rubber and acrylic polypropylene and polyethylene foam adhesives are formulated for sustained, low-irritability skin contact and have been assessed per ISO 10993 guidelines for skin-contact properties. For example, Mactac offers cross-linked polyethylene foam solutions that meet these guidelines.

Adhesive Customization Ensures Function and Experience

Above all else, chosen adhesives need to meet two primary goals: functionality and user experience. Without question, adhesives should perform as intended and adhere well per the requirements of the technology while also delivering an easy, pain-free, and comfortable user experience.

Generally speaking, medical-grade adhesives offer varying levels of adhesion—from low or soft to high or extra strength. With today’s adhesive advancements, these adhesion levels can be achieved with both acrylic and rubber adhesives. However, acrylic and rubber adhesives certainly aren’t interchangeable as each offers different performance attributes.

Rubber adhesives are ideal for short-term wearable applications, such as one day or less. They are also typically more cost-effective than acrylic adhesives and are more aggressive for multiple skin types. Acrylic adhesives are best for longer-wear applications (multiple days at a time) and are often much more breathable and stretchable than rubber adhesives. Newer medical-grade acrylics also feature quicker cure times, higher initial tack and high-shear strength, which allows them to better resist harsh environments and maintain adhesion after exposure to water or other fluids.

To determine the most ideal adhesive to use in each of today’s trending direct-skin wearable medical technologies—continuous-temperature remote monitoring, heart monitoring, glucose monitoring and TENS electrodes devices—design engineers, converters, and device manufacturers need to first answer questions such as the following:

  • What is the intended length of wear? 
  • What is the technology’s most common user skin-type? 
  • What environmental conditions does the technology need to withstand? 
  • What is the typical activity level of the technology’s user?
  • What is the overall weight of the technology and what is the size of the skin contact area

Above image courtesy of Mactac. Mactac’s single-coated non-woven tapes are available in various sizes and weights and are known for their high MVTR and high adhesion properties.

From this information, design engineers, converters and device manufacturers can identify adhesive characteristics required, such as breathability, conformability, thickness, strength, skin compatibility, latex-free and hypoallergenic properties, moisture vapor transmission rates (MVTR), fluid barrier abilities, and removability.

They can then determine whether the adhesive should be rubber or acrylic as well as the proper adhesive carrier—another highly important component of adhesive construction in direct-skin applications. Carriers can be free films or transfer tapes or single- or double-coated films, foams, non-woven fabrics, or elastic fabrics. The following offers recommendations on adhesive carriers that are most ideal for today’s trending direct-skin wearable medical technologies.

Continuous-temperature remote monitoring patches. Since continuous-temperature flexible patches are most often used on patients with delicate skin who require comfort and superior wearability, acrylic polypropylene or polyethylene foams are great choices for this trending application. Foams, while they aren’t breathable, are known for softness and conformability, delivering a more comfortable user experience than other carriers, such as films. Additionally, foam tapes enhance application stability and offer exceptionally clean, pain-free adhesive removability.

Acrylic non-woven adhesives are also another great option for flexible patch technologies. Non-woven adhesives often pair well with the needs of the technology because they can be used for longer periods of time and are extremely soft and comfortable, as well as water-resistant.

Heart-monitoring devices. With heart-monitoring device technologies, electrodes are applied and re-applied to the skin often, making films ideal for these applications. Many gentle, skin-friendly acrylic films can handle re-application extremely well.

Acrylic foams are also an ideal choice for heart-monitoring devices. Although heart-monitoring devices are often composed of difficult-to-adhere-to low-surface energy (LSE) substrates, there are several newer medical-grade acrylic foam adhesives on the market today that adhere extremely well to these materials. These innovative adhesives are soft enough to flow onto challenging substrates, but hard enough to resist flow with applied stress so they can be applied and removed from skin without developing an adhesive bond that is too strong.

Glucose-monitoring devices. Like with heart-monitoring devices, films and foams are also recommended for glucose monitoring devices. With glucose monitoring, a high-tack, soft acrylic film or foam that can hold the adhesive comfortably in place for several days – as many as 14 days in some cases – are optimal solutions.

TENS electrodes devices. As TENS electrodes applications are designed to be shorter-wear and the adhesive is removed often, non-woven adhesives are generally the best choice for this application. Today, many lightweight non-woven rubber adhesives, such as non-woven polyesters, feature lower adhesion levels, which offer greater flexibility and range of motion for the user. These adhesives help ensure TENS electrodes will stay in place yet easily move with the skin, deliver necessary breathability, and remove cleanly and painlessly.

Foam tapes are also an ideal adhesive option for TENS electrodes applications.

Proper Adhesives Make a Proper Product

As converters, design engineers, and manufacturers continue to develop and produce direct-skin wearable medical technologies, such as today’s trending continuous-temperature remote monitoring devices, heart monitoring devices, glucose monitoring devices, and TENS electrode therapy devices, adhesives will continue to play a key role in finished products. For ultimate success, adhesives should be customized specifically for each technology to meet performance and function needs and deliver users an easy, pain-free and comfortable experience.


Source: https://www.mddionline.com/adhesive-considerations-direct-skin-wearable-medical-technologies

Senate Vote To End Shutdown Would Stop Medical Device Tax Once Again by Bruce Japsen

960x0.jpg

The U.S. Senate’s vote on Monday overwhelmingly supporting legislation to re-open the federal government at least through the first week in February also included another two years of tax relief for the medical device industry.

An unpopular tax on medical device sales under the Affordable Care Act wasn’t addressed in the Republican-led Congress’ massive $1.5 trillion tax overhaulthat passed the U.S. House and Senate a month ago.

But medical device makers may finally get their legislative victory after the Republican-led Senate included a temporary end to the tax for another two years by a bipartisan vote of 81 to 18. The 2.3% tax on medical device sales had been on a temporary hiatus from the beginning of 2016 through the end of last year.

 

The U.S. House is expected to pass the Senate legislation soon.

“Congress' action to once again suspend the medical device tax – just days before companies were set to start cutting checks to the IRS – means funds will not be diverted from investing in new jobs, new capital improvements and new treatments and cures,” Advanced Medical Technology Association (AdvaMed) CEO Scott Whitaker said in a statement Monday afternoon.

The House of Representatives is also expected to include the medical device tax when it votes. The House had already agreed to put the medical device tax on a two-year hiatus in its government funding measure last week before the Senate balked Friday night and triggered the three-day federal government shutdown.

Getting a suspension of the medical device tax into legislation that would ultimately pass both chambers of Congress has been tough despite a history of bipartisan support.

A permanent repeal of the device tax fell victim to the numerous failures to repeal and replace the ACA, also known as Obamacare, after Republicans took control of both houses of Congress and the White House with the election of Donald Trump.

The Joint Committee on Taxation has said repealing the medical device tax would cost the U.S. Treasury about $20 billion over a decade. Before it was put on hiatus, the IRS collected between $1 billion and $2 billion a year in 2013, 2014 and 2015.

AdvaMed represents hundreds of medical device makers, including Abbott Laboratories, Johnson & Johnson, Medtronic, Stryker and Zimmer.

Device makers say the device tax hurt medical innovation, particularly at small firms, given that one-third of device makers have 20 or fewer employees.

“While the two-year suspension is welcome, it is only an interim step toward the truly needed action by Congress to fully repeal this tax and unleash the promise of medtech innovation,” AdvaMed’s Whitaker said. “We look forward to continuing to work with the Hill on a bipartisan basis to drive towards permanent relief.”

 

Source: https://www.forbes.com/sites/brucejapsen/2018/01/22/senate-vote-to-end-shutdown-also-ends-medical-device-tax-once-again/#134c8dda3d98

Are Implanted Medical Devices Creating A 'Danger Within Us'? by Jeanne Lenzer

download.jpg

DAVE DAVIES, HOST:

This is FRESH AIR. I'm Dave Davies in for Terry Gross who's off this week. Our guest Jeanne Lenzer is a former physician's associate who worked for years in emergency rooms until medical studies showed a treatment she and others used for chest pain was actually causing deadly heart rhythms. Her search to understand what went wrong led her to a new career as an investigative medical journalist. Her new book is about the potential dangers of the millions of medical devices implanted in our bodies - artificial joints, cardiac stents, surgical mesh and pacemakers, among many others.

Lenzer says medical devices are approved with far less scrutiny than drugs, and many high-risk devices go to market without clinical trials. Lenzer writes about several devices that have proved problematic. And her book focuses in some detail on a treatment for patients with drug-resistant epilepsy. An electrical device is implanted in the patient's body that sends regular impulses to the vagus nerve, which runs from the brain down through the neck, chest and abdomen.

A review of clinical studies by the Cochrane collaborative found the vagus nerve stimulator effective in reducing seizures for people whose epilepsy does not respond well to drugs or for whom surgery is not a good option. The Cochrane review also found that more studies needed on the effectiveness and side effects of VNS therapy. Lenzer says there's reason to believe the VNS device can cause deadly cardiac symptoms, and that it's been approved with virtually no research on how many patients implanted with VNS die.

Jeanne Lenzer is a longtime contributor to The BMJ, formerly the British Medical Journal, and her writing has appeared in The New York Times Magazine, The Atlantic and other publications. Her new book is "The Danger Within Us."

Well, Jeanne Lenzer, welcome to FRESH AIR. Do we know how often medical treatments cause problems and harm people - essentially, the cure becoming the cause of injury?

JEANNE LENZER: We don't. There are people with the Lown Institute and other places that are trying to get some numbers on this, but it's very hard to estimate how often drugs and devices are unnecessary and how many people they're harming. One of the problems with devices is that nobody's really tracking the numbers of harm - or the rates of harm, I should say.

So the FDA has a database where doctors and hospitals can report deaths and serious adverse events, but they don't know how many people are implanted with a particular device. So if you have 100 deaths in a database from a particular device - I mean, if there are only 200 of those devices implanted in people, that's really scary. If there are 2 million people implanted, that's another story. And that's exactly what we don't know because the FDA doesn't require manufacturers to report how many people are implanted.

DAVIES: And it's not that hard. We plant chips in our cats to keep track of them, right?

LENZER: Right, yes. And Walmart tracks how many heads of lettuce they have on a shelf at any given time, and they know exactly how many heads of lettuce they have to replace. They can track those a lot better than we're tracking medical devices implanted in people.

DAVIES: You know, we're aware of some awful stories about medications - drugs that prove to be problematic, like Vioxx. But you say we're a lot less skeptical about devices that get implanted in our bodies. There are a lot of them. Just give us some examples of things that we're carrying around in our bodies - medical devices.

LENZER: So there's everything from what seem like very low-risk devices like surgical mesh that's put in women to prevent stress incontinence - urinary incontinence, used in men for hernias, all the way up to implanted cardiac defibrillators and pacemakers all the way to deep-brain stimulators, Wi-Fi-enabled, computer-chipped devices, as well as combination devices that actually have drugs embedded in the device. So there's drug-eluting stents. There's spine implants that have biologic products implanted with it that have caused serious drug reactions and death.

And the problem with devices is - you know, there's several problems that are actually unique to devices compared to drugs that are actually far more concerning. One is that you often can't remove the leads from drugs. So there's wire leads going from many devices - into the brain, into the heart, on the vagus nerve. And these often become embedded in scar tissue, and you can't remove them. They can also interfere with CAT scans. And turning them off electrically, sometimes only the specialists know how to do that. And there's some horrific cases of patients being - where the electrical impulses are affecting them in a way that's very painful, and it takes quite a while for them to turn off the device.

DAVIES: You know, drugs are regulated and devices are by the Food and Drug Administration. And you note that for a new drug the FDA typically requires at least two randomized trials, so there's some sense of whether it's safe and effective. What's required of manufacturers of new medical implants?

LENZER: Well, to explain that, I have to go back to 1976 which is the year that devices came under the regulatory authority of the FDA. Prior to that, there were lots of implanted devices. There were pacemakers. There were artificial hips. And what the FDA did in 1976, when they took control of approving devices, is they said, OK, you guys are already all on the market. You can stay on the market. We'll divide you up into three classes - low-risk, medium-risk and high-risk. That's Class I, II and III. And the high-risk devices, you're going to have to prove that you're safe after you're on the market. Well, the problem is most companies never submitted any safety studies afterwards. And in fact, a study showed that five years after a device was on the market, and they required a post-approval study, 40 percent had never been conducted.

DAVIES: I just want to make sure I understand this. You had to show the studies after it was already on the market - after thousands of people have the devices implanted.

LENZER: Sure. And even now, when a new device comes on the market, like the vagus nerve stimulator, the company - it's not uncommon for companies to be required to prove safety after it's on the market. And the tragedy with the vagus nerve stimulator is they actually gave just conditional approval to the device. And the reason for that was they were concerned - and this is a direct quote from the FDA transcripts. During the scientific review, one of the scientists said, I'm concerned about the high rate of deaths among these patients in test studies and who were implanted prior to approval. So the FDA panel decided that they would just give conditional approval - meaning that, OK, we don't know if it's safe, but you'll have to prove it's safe after it's on the market.

DAVIES: I want to talk about one very specific case that you discuss at length. But first, you know, you describe how we got to this situation where there are so many devices that seem to be relatively loosely regulated. And you're right. There are three major developments - one, an explosion of medical technology starting in the '60s. A second development was the passage of Medicare in 1965 and the growth of private insurance. How did that affect this?

LENZER: Well, until the 1950s, medical care was very cheap. I mean, in fact, a study in the early 1900s showed that the biggest loss when people were hospitalized wasn't medical costs. It was simply the loss of pay from work. There wasn't much that people did in hospitals other than have a nurse maybe to cater to them, so they could stay in bed or some cheap antibiotics for pneumonia. That was about it. The problem with the explosion of medical technology in the '70s when the first CAT scans and MRIs came on the market is that they were so expensive that the average person couldn't afford it. And that meant there was a very limited market for those kinds of tests.

But with Medicare - and at the time, Medicare was enacted. It was opposed as socialized medicine, but it was actually the exact opposite of socialized medicine. It was actually fee for service. Doctors could charge anything they wanted to charge - whatever they considered customary and usual costs, which meant that their prices exploded. And they would charge that to the government. And there was no cap on the government payments.

So we then had a whole group of older people who are insured essentially through taxes by the government. But doctors were charging on fee for service. Then what that meant was that regular care for people had really transformed. I mean, now we had ways of treating people that were very different than before. But all the people who weren't covered by Medicare certainly couldn't afford it. So then we got private insurance to cover those people.

DAVIES: Right, so there was, in a sense, a huge market and a lot of money to be made if you could figure out a device that physicians and hospitals wanted to implant.

LENZER: Absolutely.

DAVIES: You also - another develop you said was an act of Congress in 1980. Explain this and why it mattered.

LENZER: So that was the Bayh-Dole Act. And with that act, what they did was encourage what they call technology transfer so that universities, for the first time, could actually patent rights. And academics were encouraged to partner with industry. And the whole point of a university, theoretically, was to have an independent place of inquiry where they didn't have to have fear or favor regarding what they found. And if they found that certain chemicals were dangerous - environmental toxins, whatever - they were supposed to be able to do that without - again, without fear or favor.

But by partnering with industry, that all began to change. And we began to see research that was basically entirely controlled by industry. And that's what we have today. Most research is actually either conducted solely by industry, or it's partnered with academia and with the national institutes of health.

DAVIES: And so - and if industry is funding a lot of research and funding chairs and positions and faculty, there's a financial interest to, you know, to do things that gets the industry where it wants to be with a particular drug or device.

LENZER: Yeah. And that's not just conjecture. There are multiple studies that look at behavior and outcomes and interpretations of medical studies when they're conducted by industry versus by truly independent sources. And invariably, what we find is that industry accentuates the positive and eliminates the negative. I mean, they have repeatedly been found guilty of suppressing bad outcomes, and they get fines for this regularly. In my book, I list numerous fines that companies have paid over and over again for concealing deaths and bad outcomes. And they just consider that part of the cost of doing business.

DAVIES: You know, this collaboration between medical research and academic research and private industry, I mean, obviously, presents at least the potential for conflicts of interest. The argument on the other side is, you know, we want these brilliant minds in academic institutions to be producing stuff that helps us - that actually improves our lives. That was the idea behind the act, wasn't it?

LENZER: Maybe. I mean, I think we have to question how much we're being flooded with dangerous things when we do that. I mean, there's upsides and downsides to every course of action. And certainly, we want to be able to transfer the knowledge that is obtained independently to people who will market these products. But I think that what we need is a clear dividing line in these roles so that we don't have industry telling us what's safe and what's not safe. They should produce the products. And we need to have independent assessments of those products.

I mean, think of it like cars. Would you go to Toyota to ask which car is the best car on the road or the most fuel-efficient car or the safest car? I mean, most of us would want to go to consumer reports or some independent entity. And that's what most of us want for medical research. We shouldn't have to go to Medtronic to ask what's the best way to treat back pain.

DAVIES: Our guest is Jeanne Lenzer. She is a medical journalist and has a new book about problems with implanted medical devices. It's called "The Danger Within Us." We'll continue our conversation in just a moment. This is FRESH AIR.

(SOUNDBITE OF TODD SICKAFOOSE'S "TINY RESISTORS")

DAVIES: Our guest is Jeanne Lenzer. She is a medical journalist who has a new book about problems with implanted medical devices. It's called "The Danger Within Us."

There's a guy whose story runs through the book that illustrates one of these cases. He's a man named Dennis Fagan, who was a firefighter and paramedic in Corpus Christi, Texas. First of all, just explain what was the medical condition that he faced.

LENZER: So he had epilepsy. And he was managed with medicines for many years.

DAVIES: And they - the seizures became more and more troubling, and he needed something different. And so he turned to this - his neurologists, I guess, suggested this medical device. Tell us what it was and what it - what it is and what it does.

LENZER: So he recommended a vagus nerve stimulator. He wasn't all that enthusiastic about recommending it, but it was sort of a last-choice option. And Dennis was ready to try anything, so he had this vagus nerve stimulator implanted. And it's like a little matchbox-sized generator that's put under the collar bone a lot like a pacemaker. And then lead wires - these wires are tunneled under his collarbone up to the neck where the vagus nerve is. That was the idea - that it would stimulate the vagus nerve and, therefore, stop his seizures.

DAVIES: And explain...

LENZER: Or at least reduce them.

DAVIES: And explain what the vagus nerve is.

LENZER: So the vagus nerve is a long nerve that runs from the brain all the way down to the anus. And it basically sends branches out to every organ of the body, regulating virtually every function in our body from heart rate to digestion to orgasm and elimination.

DAVIES: All right. So this was marketed by a company called Cyberonics, right?

LENZER: Yes.

DAVIES: Just tell us a little bit about what this company is and what made them think that stimulating the vagus nerve would have a positive impact on epileptic seizures.

LENZER: It's not really clear. I mean, there was a fellow who first got involved in patenting it for seizures and - Jacob Zabara. And he tells a story about watching his wife do Lamaze breathing during childbirth. And he says that that made him wonder if the vagus nerve could somehow mediate what was going on, that she was moderating her pain with this breathing which is mediated through the vagus nerve. And he wondered if that could somehow affect seizures. And then they ran a couple studies. The first study the FDA did not approve.

And the second study that they demanded was the basis for approval, even though there are some questions about whether it really showed any significant difference in seizures. It depended on the way you looked at the study and the way you divided up the numbers. The bigger problem was that how many people died. And that was the rationale for FDA, when it considered the device, only gave conditional approval for the device. The problem is that the basis of that approval, the conditional approval based on the concern about a high number of deaths, high rate of deaths, is that they weren't required to tell patients this.

DAVIES: So the FDA gave it conditional approval because there was concern about deaths. What happened next? Did it go on the market?

LENZER: Well, the idea - yeah, it went on the market in 1997. And the idea of conditional approval is that once the company proves it's safe after it's on the market, then its approval is complete. When Dennis Fegan contacted me, one of the first things I did was go to the company - and this is a dozen years after it was on the market - and asked them for the evidence that the device was safe. Had they ever proved it was safe? And they sent me five studies. And I read all five studies very carefully, and not one of them reported any deaths. It's not that they reported there were no deaths, it's that they had no report about deaths.

So I called the FDA and asked them for what evidence they had the device was safe. And they said, oh, it's safe. We'll send you our evidence. And they sent me the exact same five studies that the company had sent me. So I thought I must be missing some unpublished data here. I went back to the company and said, do you have unpublished data about deaths? I need to know about deaths. That's why this device was approved conditionally. And they said, we never collected data on deaths.

So for the five studies that they submitted, they never recorded how many people died, if they died, when they died. And then when I pressed them, they said, well, we did collect mortality data from the Social Security Death Index. And I said, well - you know, at the time, I was writing for the British Medical Journal. And I asked to release those data on behalf of the British Medical Journal. And they refused to release the death data.

So I went back to the FDA certain the company was going to get slammed. I mean, here it is. Here's a device on the market over a decade after it was approved, and yet, they'd never done a study looking at deaths, nor would they release the death data. And when I brought all this to the FDA, the FDA said, it's safe. And I said, how can you say it's safe when we don't have death data? And their answer - and I have it in writing - is we never asked the company to count the number of deaths. We only asked them to characterize death.

DAVIES: Meaning what?

LENZER: (Laughter) Well, how you can characterize deaths without knowing if anybody died is anybody's guess. I mean, theoretically, you can say, well, the idea is, did they die of pneumonia? Or did they die of sudden heart death? You know, those might give you clues into the problem. But how do you report the nature of a death if you're not collecting any death data?

And what I really think is important here is not just about the VNS device. VNS is just an example of many devices like this. Again, like I said, 40 percent of conditional approvals haven't had a post-approval study five years after it's on the market. So people are being subjected to devices that scientists may have had serious concerns about, and yet, they don't even know if they're safe or not.

DAVIES: Jeanne Lenzer is a medical journalist. Her new book about medical devices is called "The Danger Within Us." After a break, she'll tell us about Dennis Fegan's near-death experience in an emergency room. Also, David Bianculli reviews "Electric Dreams," a new Amazon series based on the works of Philip K. Dick and the new season of "Black Mirror" on Netflix. I'm Dave Davies, and this is FRESH AIR.

(SOUNDBITE OF MUSIC)

DAVIES: This is FRESH AIR. I'm Dave Davies in for Terry Gross, who's off this week. We're speaking with medical journalist Jeanne Lenzer, who's written a new book about the risks and implanted medical devices such as artificial joints, cardiac stents and pacemakers. She says they're approved with far less scrutiny than new drugs, and some can cause serious harm. Her book is called "The Danger Within Us."

I want to return to the story of Dennis Fegan. Dennis Fegan, this firefighter and paramedic who suffered from epileptic seizures, and out of some desperation, got this vagus nerve stimulator planted in him, this little box with wires that would stimulate the vagus nerve that runs down his body and hopefully ease his epileptic seizures. He ended up in a life-threatening situation in - when was this - 2009, I guess.

LENZER: 2006.

DAVIES: 2006. Tell us what happened.

LENZER: So one night, he was awakened about a - with a pain in his throat. About 2 in the morning, he woke up. And he knew that the pain in his throat was associated with a seizure, so he got up, and he put a vertical mark on his calendar on that date. And he used that calendar for his neurosurgeon and his neurologist so that they could manage his medications.

DAVIES: So he could count...

LENZER: Well, by the...

DAVIES: ...He - it was a way for him counting them, right? Yeah.

LENZER: Yes. Yeah. And when his parents found him the next morning, they saw him stumble out of his room and fall unconscious onto the floor. And when he came to, he got up, sat down on a dining room chair and immediately fell face-first into the floor again. This time, you know, he's afraid of falling again, so he wiggles across the room with his back against the wall. His legs are splayed in front of him. His jeans are soaked with urine. He looks half dead. His parents frantically call for an ambulance. By the time the ambulance gets there, he's already passed out eight more times.

The paramedics, figuring he's having seizures - as Dennis thought he was having seizures - gave him seizure medication that they injected in his arm. But it didn't stop the seizures. So they rush him to the hospital, where the ER doctor also gives him more seizure medicine seeing his seizures. And again, he can't stop the seizures. And the ER doctor is frantic. He, you know, thumps Fegan on the chest trying to bring him back to life. And that's when he notices something very curious.

Fegan's heart is stopping at precisely three-minute intervals. This makes no sense to the ER doctor. He calls in a cardiologist. The cardiologist rushes downstairs, looks at him. They both see the same thing. And it's only when the neurologist arrives - Fegan's neurologist - who says, oh, Fegan has a VNS device, and it's set to fire at exactly three-minute intervals. So the device, instead of stopping his seizures, was stopping his heart. So they rushed to turn off the device. And when they finally get it turned off, the seizures stop immediately and Fegan doesn't have anymore. They send him up to the ICU to recover. And the next day, Fegan learns that his heart has been stopped by the device. And that launches him into a decade-long battle with FDA, regulatory authorities and the device manufacturer.

DAVIES: So to be clear, there was this unanswered question about how many deaths might be associated with the vagus nerve stimulator. And in this one specific case, we find that every three minutes, as the stimulator fires its electronic pulse, this man's heart stops. And that ends when the device is disabled, right?

LENZER: Right. And Fegan gets concerned about other people implanted with the device and wants to know whether it's happening to other people, so he finds out about the FDA's MAUDE database. It's a database where all device adverse events are kept. And when he looks into the database, he sees that many people have actually had very similar experiences to his own, but also, many have died. And he's wondering, you know, if I'd been found dead, he told me, everybody would have said I died of epilepsy rather than the device. And it's only because he lived and there's a recording in the ER of what happened to him that anyone knows it wasn't because of epilepsy. It was because of the device.

DAVIES: This raises one of the interesting issues about these devices and their regulation. The FDA has this database at which physicians and hospitals are expected to report problems - adverse events with medical devices. Sounds like it would be a smart way - and the FDA says it is the way - we look for red flags. Why doesn't it work better?

LENZER: Well, first of all, there's a study showing that only about 1 percent of all serious adverse events make it into the FDA's adverse event database. And something that really surprised me was, it turns out that the more serious the event was, the less likely it was to be reported. Manufacturers are supposed to report these adverse events. And there is some leeway granted to them about determining whether the device event was related or not to the device.

So, you know, sometimes people cough and sneeze when they have a device. It doesn't mean the device caused it. The problem is is that there's no independent party assessing whether these problems are related to the device or not. So leaving that decision to the company presents a real conflict of interest.

DAVIES: Yeah. So, for example, if someone died because this stimulator had actually stopped his heart, it could appear to be epilepsy and therefore would not appear as an adverse event associated with the device.

LENZER: Absolutely.

DAVIES: Right, right.

LENZER: That's a big problem. And that's something that I refer to as cure as cause, where - doctors assume that when a patient dies - and I did too when I was in practice - that a patient has a heart attack, they died of a heart attack and the bad heart rhythm that went with it. We don't assume that it's the drug or the device that we prescribed for the patient. And that's a real problem because it turns out that the kind of studies we need - there really shouldn't even be a decision about whether a side effect is due to the device or not.

We should just count up all the adverse events, all the deaths that occur in the patients who are implanted and in the control group. And that would give us a far better picture because it turns out that the kind of studies we need - there really shouldn't even be a decision about whether a side effect is due to the device or not. We should just count up all the adverse events, all the deaths that occur in the patients who were implanted and in the control group. And that would give us a far better picture of what's going on.

DAVIES: Coming back to Dennis Fegan, he was obviously deeply troubled by what happened in the emergency room and started gathering information about this. He also decided he wanted the vagus nerve stimulator removed, and he consulted a surgeon about that. What did he learn?

LENZER: Well, he was told that he could have the generator taken out but not the lead wires, the lead wires that tunneled up to his neck and were wrapped around the vagus nerve because many surgeons have found that the wires become enmeshed in scar tissue. And it just becomes too dangerous to try to tease those wires out of the scar tissue. They can tear and destroy the very nerves that are next to them and even the jugular vein and the carotid artery that are right adjacent to the vagus nerve. So it's too dangerous a surgery, and they left the lead wires in but took the generator out.

DAVIES: Dennis Fegan was frustrated by what happened to him, and one of the things he considers is a lawsuit. It turns out he is unable to sue and he learns why. What's going on here?

LENZER: Well, it turns out there was a Supreme Court ruling in 2008 called Riegel v. Medtronic, and it's also called the pre-emption ruling. And what it means is that patients who are implanted with high-risk devices that went through the premarket approval process called PMA are not allowed to sue. And the basis for that is - is that supposedly they underwent rigorous testing proving the device was safe.

DAVIES: So patients can sue in the case of a drug that they think has harmed them but not in devices that have gone through this process.

LENZER: Not in certain devices - that's right - certain high-risk devices.

DAVIES: Jeanne Lenzer is our guest. She's a medical journalist, and she has a new book about problems with implanted medical devices. It's called the danger within us. We'll talk some more after a short break. This is FRESH AIR.

(SOUNDBITE OF MUSIC)

DAVIES: This is FRESH AIR, and we're speaking with Jeanne Lenzer. She is a medical journalist. She has a new book called "The Danger Within Us: America's Untested, Unregulated Medical Device Industry And One Man's Battle To Survive It."

You argue in this book that the FDA does a bad job of regulating these devices because they've become heavily influenced, maybe even captured by the industries they regulate. This is a big subject, but briefly, what's the evidence of that? What's happened here, do you think?

LENZER: Well, part of the problem is - is that the FDA commissioner, the lead legal counsel used to be civil servants who came up from within without having to fear political interference. There's a former FDA scientist who told me that decades ago - yeah, they might get a call from a politician now and again and say, hey, what's going on that you're holding up this device approval or that problem? And he said, you know, we'd explain it, and that would be the end of it.

That's no longer the case. We've had a number of instances now, including an episode dubbed Devicegate in which all of the scientists agreed that certain devices should not be approved because they were unsafe and ineffective. And yet the devices were put on the market over the unanimous opinion of their own scientists when politicians made phone calls to FDA superiors. This is really stunning that politics is trumping science. And it's getting worse now with 21st Century Cures Act that was passed in late 2016, which essentially is deregulating even further.

DAVIES: You know, most of us ordinary patients in the world aren't going to do research about medical devices, right? We're going to trust doctors to know what works and what is safe. Broadly speaking, should we?

LENZER: This is a terrific problem. I mean, I have a medical device implanted. I'm very happy with it, but I got to confess. I didn't research it because the truth is we are dependent on the research that comes out of these companies. And that's where I wanted to alert the public that we need to make some structural changes so that we can trust these devices. As you said, we can't individually research them because we don't have the capability to do it. Even if we read the studies that are released, we don't know that we can trust them.

And I'll give you two examples of just how difficult the situation is. One of the people I talk about in the book is a man who was harmed by a hip implant. Well, it turns out that man is also an orthopedic surgeon who specializes in hip replacements, and yet he landed up being poisoned by his hip implant from cobalt that leaked out of the hip and destroyed his muscles and tissues and even caused some degree of heart damage.

Another example is a Medtronic executive that I report on who had a Medtronic device implanted in her spine and suffered just terribly disabling and painful effects from that device. So even people who are insiders and who should know don't really know.

DAVIES: So how do we protect ourselves? What should we do?

LENZER: I don't really think there's any individual way to find out which devices are really safe, except I'll say this. You can go and check the FDA's database and look up the device and see if there are warnings about it. But beyond that, if it's a device that's recommended, many of them do work great. I mean, lives are being saved and transformed in many positive ways. And that's part of what troubles me. I mean, I wouldn't have bothered with this if I didn't feel that there was some merit in the field. Medical devices can be wonderful. What we need is to be able to tell the difference between the ones that don't work and the ones that do work.

DAVIES: You know, we focused a lot on this one case - the vagus nerve stimulator. You write about several others in the book. Are there other devices that are particularly problematic?

LENZER: Yes. The Sprint Fidelis leads that go to defibrillators pacemakers were found to have fractured and cause serious injury and death. And these were implanted in hundreds of thousands of people. And this is one of the problems with devices - is that, you know, what do you do once you're implanted with something that may be dangerous? Having them removed in 15 to 18 percent of people, nearly 1 in 5 people suffered serious adverse events or death when they tried to remove the leads.

Hip implants have leaked chromium and cobalt, and there are other problems. Pelvic mesh - again, a seemingly simple device. It's just mesh after all - surgical mesh. And yet it has grated through tissues like a cheese grater through cheese and caused what's called fistulas - holes between the rectum and the vagina and causing serious pain, infections, hemorrhage. There are all kinds of problems with medical devices that people might want to think about first.

And one of the common things I hear from patients is, you know, now that I think of it, my problem wasn't that serious. So a woman who has a little bit of urinary dribbling when she sneezes or gets excited goes and gets this pelvic mesh put in because a doctor recommends it and then has a lifetime of pain, infections and suffering. So I guess my best advice would be, if you're not certain you really need something, it might be best to wait.

DAVIES: Right. If you take a medication, you can always stop. When you...

LENZER: Yes.

DAVIES: And when you put something inside your body, as you say, the leads may sometimes fuse onto other - create scar tissue and - yeah.

LENZER: And ask if your ER doctors know how to take care of you. I mean, there was one tragic case of a woman with a vagus nerve stimulator who called her sister saying, oh, my God, my VNS is shocking me. I can feel it. It's so painful. I dropped to my knees. And her sister told her, go. Go straight to the ER.

And the young woman who was about 39 years old, a young mother, said, I can't because they don't have the tools to turn this off. I have to wait until my doctor comes in on Monday morning. She didn't get to see her doctor on Monday morning because her 9-year-old daughter found her dead in the bathroom on Sunday night.

DAVIES: You know, this book is powerful. And I could imagine some looking at it and saying, you know, this is too dark a portrait, that there's always risk in treatment and that, you know, people do suffer from conditions that these devices can - are intended to treat and that, you know, you focused on all the problems and maybe given too little attention to people who, you know, are happy with devices that have changed their lives. How would you respond to that?

LENZER: Well, fair enough in terms of my book - not so fair in terms of the total literature out there. And that's why I did focus on the problems because there's a lot of rah-rah information about devices. Everybody's tech-happy and thinks that the newest cutting-edge device must be better than the older device and - when in fact that's not always the case. In fact, when you look at the Sprint Fidelis leads, they were a slight tweak to older leads where they made them somewhat thinner to be more flexible. The problem is, is they were thinner and therefore broke.

So newer isn't always better, and all the excitement about high-tech stuff needs to be moderated with an understanding that these things sometimes cause serious harms. And all I want is for patients to be able to learn the truth so they can make their own assessment about whether they want a device. I want people who have epilepsy to be told the truth about the side effects and downsides as well as the upsides. And that's true for all devices.

DAVIES: Jeanne Lenzer, thank you so much for speaking with us.

LENZER: Thank you. Thank you for having me.

DAVIES: Jeanne Lenzer is an investigative medical journalist. Her new book about implanted medical devices is called "The Danger Within Us." Coming up, David Bianculli reviews the new Amazon series "Electric Dreams" based on the works of Philip K. Dick and the new season of "Black Mirror" on Netflix. This is FRESH AIR.


Source: https://www.npr.org/2018/01/17/578562873/are-implanted-medical-devices-creating-a-danger-within-us

Are Implanted Medical Devices Creating A 'Danger Within Us'? by Dave Davies

download (2).jpg

DAVE DAVIES, HOST:

 

This is FRESH AIR. I'm Dave Davies in for Terry Gross who's off this week. Our guest Jeanne Lenzer is a former physician's associate who worked for years in emergency rooms until medical studies showed a treatment she and others used for chest pain was actually causing deadly heart rhythms. Her search to understand what went wrong led her to a new career as an investigative medical journalist. Her new book is about the potential dangers of the millions of medical devices implanted in our bodies - artificial joints, cardiac stents, surgical mesh and pacemakers, among many others.

Lenzer says medical devices are approved with far less scrutiny than drugs, and many high-risk devices go to market without clinical trials. Lenzer writes about several devices that have proved problematic. And her book focuses in some detail on a treatment for patients with drug-resistant epilepsy. An electrical device is implanted in the patient's body that sends regular impulses to the vagus nerve, which runs from the brain down through the neck, chest and abdomen.

A review of clinical studies by the Cochrane collaborative found the vagus nerve stimulator effective in reducing seizures for people whose epilepsy does not respond well to drugs or for whom surgery is not a good option. The Cochrane review also found that more studies needed on the effectiveness and side effects of VNS therapy. Lenzer says there's reason to believe the VNS device can cause deadly cardiac symptoms, and that it's been approved with virtually no research on how many patients implanted with VNS die.

Jeanne Lenzer is a longtime contributor to The BMJ, formerly the British Medical Journal, and her writing has appeared in The New York Times Magazine, The Atlantic and other publications. Her new book is "The Danger Within Us."

Well, Jeanne Lenzer, welcome to FRESH AIR. Do we know how often medical treatments cause problems and harm people - essentially, the cure becoming the cause of injury?

JEANNE LENZER: We don't. There are people with the Lown Institute and other places that are trying to get some numbers on this, but it's very hard to estimate how often drugs and devices are unnecessary and how many people they're harming. One of the problems with devices is that nobody's really tracking the numbers of harm - or the rates of harm, I should say.

So the FDA has a database where doctors and hospitals can report deaths and serious adverse events, but they don't know how many people are implanted with a particular device. So if you have 100 deaths in a database from a particular device - I mean, if there are only 200 of those devices implanted in people, that's really scary. If there are 2 million people implanted, that's another story. And that's exactly what we don't know because the FDA doesn't require manufacturers to report how many people are implanted.

DAVIES: And it's not that hard. We plant chips in our cats to keep track of them, right?

LENZER: Right, yes. And Walmart tracks how many heads of lettuce they have on a shelf at any given time, and they know exactly how many heads of lettuce they have to replace. They can track those a lot better than we're tracking medical devices implanted in people.

DAVIES: You know, we're aware of some awful stories about medications - drugs that prove to be problematic, like Vioxx. But you say we're a lot less skeptical about devices that get implanted in our bodies. There are a lot of them. Just give us some examples of things that we're carrying around in our bodies - medical devices.

LENZER: So there's everything from what seem like very low-risk devices like surgical mesh that's put in women to prevent stress incontinence - urinary incontinence, used in men for hernias, all the way up to implanted cardiac defibrillators and pacemakers all the way to deep-brain stimulators, Wi-Fi-enabled, computer-chipped devices, as well as combination devices that actually have drugs embedded in the device. So there's drug-eluting stents. There's spine implants that have biologic products implanted with it that have caused serious drug reactions and death.

And the problem with devices is - you know, there's several problems that are actually unique to devices compared to drugs that are actually far more concerning. One is that you often can't remove the leads from drugs. So there's wire leads going from many devices - into the brain, into the heart, on the vagus nerve. And these often become embedded in scar tissue, and you can't remove them. They can also interfere with CAT scans. And turning them off electrically, sometimes only the specialists know how to do that. And there's some horrific cases of patients being - where the electrical impulses are affecting them in a way that's very painful, and it takes quite a while for them to turn off the device.

DAVIES: You know, drugs are regulated and devices are by the Food and Drug Administration. And you note that for a new drug the FDA typically requires at least two randomized trials, so there's some sense of whether it's safe and effective. What's required of manufacturers of new medical implants?

LENZER: Well, to explain that, I have to go back to 1976 which is the year that devices came under the regulatory authority of the FDA. Prior to that, there were lots of implanted devices. There were pacemakers. There were artificial hips. And what the FDA did in 1976, when they took control of approving devices, is they said, OK, you guys are already all on the market. You can stay on the market. We'll divide you up into three classes - low-risk, medium-risk and high-risk. That's Class I, II and III. And the high-risk devices, you're going to have to prove that you're safe after you're on the market. Well, the problem is most companies never submitted any safety studies afterwards. And in fact, a study showed that five years after a device was on the market, and they required a post-approval study, 40 percent had never been conducted.

DAVIES: I just want to make sure I understand this. You had to show the studies after it was already on the market - after thousands of people have the devices implanted.

LENZER: Sure. And even now, when a new device comes on the market, like the vagus nerve stimulator, the company - it's not uncommon for companies to be required to prove safety after it's on the market. And the tragedy with the vagus nerve stimulator is they actually gave just conditional approval to the device. And the reason for that was they were concerned - and this is a direct quote from the FDA transcripts. During the scientific review, one of the scientists said, I'm concerned about the high rate of deaths among these patients in test studies and who were implanted prior to approval. So the FDA panel decided that they would just give conditional approval - meaning that, OK, we don't know if it's safe, but you'll have to prove it's safe after it's on the market.

DAVIES: I want to talk about one very specific case that you discuss at length. But first, you know, you describe how we got to this situation where there are so many devices that seem to be relatively loosely regulated. And you're right. There are three major developments - one, an explosion of medical technology starting in the '60s. A second development was the passage of Medicare in 1965 and the growth of private insurance. How did that affect this?

LENZER: Well, until the 1950s, medical care was very cheap. I mean, in fact, a study in the early 1900s showed that the biggest loss when people were hospitalized wasn't medical costs. It was simply the loss of pay from work. There wasn't much that people did in hospitals other than have a nurse maybe to cater to them, so they could stay in bed or some cheap antibiotics for pneumonia. That was about it. The problem with the explosion of medical technology in the '70s when the first CAT scans and MRIs came on the market is that they were so expensive that the average person couldn't afford it. And that meant there was a very limited market for those kinds of tests.

But with Medicare - and at the time, Medicare was enacted. It was opposed as socialized medicine, but it was actually the exact opposite of socialized medicine. It was actually fee for service. Doctors could charge anything they wanted to charge - whatever they considered customary and usual costs, which meant that their prices exploded. And they would charge that to the government. And there was no cap on the government payments.

So we then had a whole group of older people who are insured essentially through taxes by the government. But doctors were charging on fee for service. Then what that meant was that regular care for people had really transformed. I mean, now we had ways of treating people that were very different than before. But all the people who weren't covered by Medicare certainly couldn't afford it. So then we got private insurance to cover those people.

DAVIES: Right, so there was, in a sense, a huge market and a lot of money to be made if you could figure out a device that physicians and hospitals wanted to implant.

LENZER: Absolutely.

DAVIES: You also - another develop you said was an act of Congress in 1980. Explain this and why it mattered.

LENZER: So that was the Bayh-Dole Act. And with that act, what they did was encourage what they call technology transfer so that universities, for the first time, could actually patent rights. And academics were encouraged to partner with industry. And the whole point of a university, theoretically, was to have an independent place of inquiry where they didn't have to have fear or favor regarding what they found. And if they found that certain chemicals were dangerous - environmental toxins, whatever - they were supposed to be able to do that without - again, without fear or favor.

But by partnering with industry, that all began to change. And we began to see research that was basically entirely controlled by industry. And that's what we have today. Most research is actually either conducted solely by industry, or it's partnered with academia and with the national institutes of health.

DAVIES: And so - and if industry is funding a lot of research and funding chairs and positions and faculty, there's a financial interest to, you know, to do things that gets the industry where it wants to be with a particular drug or device.

LENZER: Yeah. And that's not just conjecture. There are multiple studies that look at behavior and outcomes and interpretations of medical studies when they're conducted by industry versus by truly independent sources. And invariably, what we find is that industry accentuates the positive and eliminates the negative. I mean, they have repeatedly been found guilty of suppressing bad outcomes, and they get fines for this regularly. In my book, I list numerous fines that companies have paid over and over again for concealing deaths and bad outcomes. And they just consider that part of the cost of doing business.

DAVIES: You know, this collaboration between medical research and academic research and private industry, I mean, obviously, presents at least the potential for conflicts of interest. The argument on the other side is, you know, we want these brilliant minds in academic institutions to be producing stuff that helps us - that actually improves our lives. That was the idea behind the act, wasn't it?

LENZER: Maybe. I mean, I think we have to question how much we're being flooded with dangerous things when we do that. I mean, there's upsides and downsides to every course of action. And certainly, we want to be able to transfer the knowledge that is obtained independently to people who will market these products. But I think that what we need is a clear dividing line in these roles so that we don't have industry telling us what's safe and what's not safe. They should produce the products. And we need to have independent assessments of those products.

I mean, think of it like cars. Would you go to Toyota to ask which car is the best car on the road or the most fuel-efficient car or the safest car? I mean, most of us would want to go to consumer reports or some independent entity. And that's what most of us want for medical research. We shouldn't have to go to Medtronic to ask what's the best way to treat back pain.

DAVIES: Our guest is Jeanne Lenzer. She is a medical journalist and has a new book about problems with implanted medical devices. It's called "The Danger Within Us." We'll continue our conversation in just a moment. This is FRESH AIR.

(SOUNDBITE OF TODD SICKAFOOSE'S "TINY RESISTORS")

DAVIES: Our guest is Jeanne Lenzer. She is a medical journalist who has a new book about problems with implanted medical devices. It's called "The Danger Within Us."

There's a guy whose story runs through the book that illustrates one of these cases. He's a man named Dennis Fagan, who was a firefighter and paramedic in Corpus Christi, Texas. First of all, just explain what was the medical condition that he faced.

LENZER: So he had epilepsy. And he was managed with medicines for many years.

DAVIES: And they - the seizures became more and more troubling, and he needed something different. And so he turned to this - his neurologists, I guess, suggested this medical device. Tell us what it was and what it - what it is and what it does.

LENZER: So he recommended a vagus nerve stimulator. He wasn't all that enthusiastic about recommending it, but it was sort of a last-choice option. And Dennis was ready to try anything, so he had this vagus nerve stimulator implanted. And it's like a little matchbox-sized generator that's put under the collar bone a lot like a pacemaker. And then lead wires - these wires are tunneled under his collarbone up to the neck where the vagus nerve is. That was the idea - that it would stimulate the vagus nerve and, therefore, stop his seizures.

DAVIES: And explain...

LENZER: Or at least reduce them.

DAVIES: And explain what the vagus nerve is.

LENZER: So the vagus nerve is a long nerve that runs from the brain all the way down to the anus. And it basically sends branches out to every organ of the body, regulating virtually every function in our body from heart rate to digestion to orgasm and elimination.

DAVIES: All right. So this was marketed by a company called Cyberonics, right?

LENZER: Yes.

DAVIES: Just tell us a little bit about what this company is and what made them think that stimulating the vagus nerve would have a positive impact on epileptic seizures.

LENZER: It's not really clear. I mean, there was a fellow who first got involved in patenting it for seizures and - Jacob Zabara. And he tells a story about watching his wife do Lamaze breathing during childbirth. And he says that that made him wonder if the vagus nerve could somehow mediate what was going on, that she was moderating her pain with this breathing which is mediated through the vagus nerve. And he wondered if that could somehow affect seizures. And then they ran a couple studies. The first study the FDA did not approve.

And the second study that they demanded was the basis for approval, even though there are some questions about whether it really showed any significant difference in seizures. It depended on the way you looked at the study and the way you divided up the numbers. The bigger problem was that how many people died. And that was the rationale for FDA, when it considered the device, only gave conditional approval for the device. The problem is that the basis of that approval, the conditional approval based on the concern about a high number of deaths, high rate of deaths, is that they weren't required to tell patients this.

DAVIES: So the FDA gave it conditional approval because there was concern about deaths. What happened next? Did it go on the market?

LENZER: Well, the idea - yeah, it went on the market in 1997. And the idea of conditional approval is that once the company proves it's safe after it's on the market, then its approval is complete. When Dennis Fegan contacted me, one of the first things I did was go to the company - and this is a dozen years after it was on the market - and asked them for the evidence that the device was safe. Had they ever proved it was safe? And they sent me five studies. And I read all five studies very carefully, and not one of them reported any deaths. It's not that they reported there were no deaths, it's that they had no report about deaths.

So I called the FDA and asked them for what evidence they had the device was safe. And they said, oh, it's safe. We'll send you our evidence. And they sent me the exact same five studies that the company had sent me. So I thought I must be missing some unpublished data here. I went back to the company and said, do you have unpublished data about deaths? I need to know about deaths. That's why this device was approved conditionally. And they said, we never collected data on deaths.

So for the five studies that they submitted, they never recorded how many people died, if they died, when they died. And then when I pressed them, they said, well, we did collect mortality data from the Social Security Death Index. And I said, well - you know, at the time, I was writing for the British Medical Journal. And I asked to release those data on behalf of the British Medical Journal. And they refused to release the death data.

So I went back to the FDA certain the company was going to get slammed. I mean, here it is. Here's a device on the market over a decade after it was approved, and yet, they'd never done a study looking at deaths, nor would they release the death data. And when I brought all this to the FDA, the FDA said, it's safe. And I said, how can you say it's safe when we don't have death data? And their answer - and I have it in writing - is we never asked the company to count the number of deaths. We only asked them to characterize death.

DAVIES: Meaning what?

LENZER: (Laughter) Well, how you can characterize deaths without knowing if anybody died is anybody's guess. I mean, theoretically, you can say, well, the idea is, did they die of pneumonia? Or did they die of sudden heart death? You know, those might give you clues into the problem. But how do you report the nature of a death if you're not collecting any death data?

And what I really think is important here is not just about the VNS device. VNS is just an example of many devices like this. Again, like I said, 40 percent of conditional approvals haven't had a post-approval study five years after it's on the market. So people are being subjected to devices that scientists may have had serious concerns about, and yet, they don't even know if they're safe or not.

DAVIES: Jeanne Lenzer is a medical journalist. Her new book about medical devices is called "The Danger Within Us." After a break, she'll tell us about Dennis Fegan's near-death experience in an emergency room. Also, David Bianculli reviews "Electric Dreams," a new Amazon series based on the works of Philip K. Dick and the new season of "Black Mirror" on Netflix. I'm Dave Davies, and this is FRESH AIR.

(SOUNDBITE OF MUSIC)

DAVIES: This is FRESH AIR. I'm Dave Davies in for Terry Gross, who's off this week. We're speaking with medical journalist Jeanne Lenzer, who's written a new book about the risks and implanted medical devices such as artificial joints, cardiac stents and pacemakers. She says they're approved with far less scrutiny than new drugs, and some can cause serious harm. Her book is called "The Danger Within Us."

I want to return to the story of Dennis Fegan. Dennis Fegan, this firefighter and paramedic who suffered from epileptic seizures, and out of some desperation, got this vagus nerve stimulator planted in him, this little box with wires that would stimulate the vagus nerve that runs down his body and hopefully ease his epileptic seizures. He ended up in a life-threatening situation in - when was this - 2009, I guess.

LENZER: 2006.

DAVIES: 2006. Tell us what happened.

LENZER: So one night, he was awakened about a - with a pain in his throat. About 2 in the morning, he woke up. And he knew that the pain in his throat was associated with a seizure, so he got up, and he put a vertical mark on his calendar on that date. And he used that calendar for his neurosurgeon and his neurologist so that they could manage his medications.

DAVIES: So he could count...

LENZER: Well, by the...

DAVIES: ...He - it was a way for him counting them, right? Yeah.

LENZER: Yes. Yeah. And when his parents found him the next morning, they saw him stumble out of his room and fall unconscious onto the floor. And when he came to, he got up, sat down on a dining room chair and immediately fell face-first into the floor again. This time, you know, he's afraid of falling again, so he wiggles across the room with his back against the wall. His legs are splayed in front of him. His jeans are soaked with urine. He looks half dead. His parents frantically call for an ambulance. By the time the ambulance gets there, he's already passed out eight more times.

The paramedics, figuring he's having seizures - as Dennis thought he was having seizures - gave him seizure medication that they injected in his arm. But it didn't stop the seizures. So they rush him to the hospital, where the ER doctor also gives him more seizure medicine seeing his seizures. And again, he can't stop the seizures. And the ER doctor is frantic. He, you know, thumps Fegan on the chest trying to bring him back to life. And that's when he notices something very curious.

Fegan's heart is stopping at precisely three-minute intervals. This makes no sense to the ER doctor. He calls in a cardiologist. The cardiologist rushes downstairs, looks at him. They both see the same thing. And it's only when the neurologist arrives - Fegan's neurologist - who says, oh, Fegan has a VNS device, and it's set to fire at exactly three-minute intervals. So the device, instead of stopping his seizures, was stopping his heart. So they rushed to turn off the device. And when they finally get it turned off, the seizures stop immediately and Fegan doesn't have anymore. They send him up to the ICU to recover. And the next day, Fegan learns that his heart has been stopped by the device. And that launches him into a decade-long battle with FDA, regulatory authorities and the device manufacturer.

DAVIES: So to be clear, there was this unanswered question about how many deaths might be associated with the vagus nerve stimulator. And in this one specific case, we find that every three minutes, as the stimulator fires its electronic pulse, this man's heart stops. And that ends when the device is disabled, right?

LENZER: Right. And Fegan gets concerned about other people implanted with the device and wants to know whether it's happening to other people, so he finds out about the FDA's MAUDE database. It's a database where all device adverse events are kept. And when he looks into the database, he sees that many people have actually had very similar experiences to his own, but also, many have died. And he's wondering, you know, if I'd been found dead, he told me, everybody would have said I died of epilepsy rather than the device. And it's only because he lived and there's a recording in the ER of what happened to him that anyone knows it wasn't because of epilepsy. It was because of the device.

DAVIES: This raises one of the interesting issues about these devices and their regulation. The FDA has this database at which physicians and hospitals are expected to report problems - adverse events with medical devices. Sounds like it would be a smart way - and the FDA says it is the way - we look for red flags. Why doesn't it work better?

LENZER: Well, first of all, there's a study showing that only about 1 percent of all serious adverse events make it into the FDA's adverse event database. And something that really surprised me was, it turns out that the more serious the event was, the less likely it was to be reported. Manufacturers are supposed to report these adverse events. And there is some leeway granted to them about determining whether the device event was related or not to the device.

So, you know, sometimes people cough and sneeze when they have a device. It doesn't mean the device caused it. The problem is is that there's no independent party assessing whether these problems are related to the device or not. So leaving that decision to the company presents a real conflict of interest.

DAVIES: Yeah. So, for example, if someone died because this stimulator had actually stopped his heart, it could appear to be epilepsy and therefore would not appear as an adverse event associated with the device.

LENZER: Absolutely.

DAVIES: Right, right.

LENZER: That's a big problem. And that's something that I refer to as cure as cause, where - doctors assume that when a patient dies - and I did too when I was in practice - that a patient has a heart attack, they died of a heart attack and the bad heart rhythm that went with it. We don't assume that it's the drug or the device that we prescribed for the patient. And that's a real problem because it turns out that the kind of studies we need - there really shouldn't even be a decision about whether a side effect is due to the device or not.

We should just count up all the adverse events, all the deaths that occur in the patients who are implanted and in the control group. And that would give us a far better picture because it turns out that the kind of studies we need - there really shouldn't even be a decision about whether a side effect is due to the device or not. We should just count up all the adverse events, all the deaths that occur in the patients who were implanted and in the control group. And that would give us a far better picture of what's going on.

DAVIES: Coming back to Dennis Fegan, he was obviously deeply troubled by what happened in the emergency room and started gathering information about this. He also decided he wanted the vagus nerve stimulator removed, and he consulted a surgeon about that. What did he learn?

LENZER: Well, he was told that he could have the generator taken out but not the lead wires, the lead wires that tunneled up to his neck and were wrapped around the vagus nerve because many surgeons have found that the wires become enmeshed in scar tissue. And it just becomes too dangerous to try to tease those wires out of the scar tissue. They can tear and destroy the very nerves that are next to them and even the jugular vein and the carotid artery that are right adjacent to the vagus nerve. So it's too dangerous a surgery, and they left the lead wires in but took the generator out.

DAVIES: Dennis Fegan was frustrated by what happened to him, and one of the things he considers is a lawsuit. It turns out he is unable to sue and he learns why. What's going on here?

LENZER: Well, it turns out there was a Supreme Court ruling in 2008 called Riegel v. Medtronic, and it's also called the pre-emption ruling. And what it means is that patients who are implanted with high-risk devices that went through the premarket approval process called PMA are not allowed to sue. And the basis for that is - is that supposedly they underwent rigorous testing proving the device was safe.

DAVIES: So patients can sue in the case of a drug that they think has harmed them but not in devices that have gone through this process.

LENZER: Not in certain devices - that's right - certain high-risk devices.

DAVIES: Jeanne Lenzer is our guest. She's a medical journalist, and she has a new book about problems with implanted medical devices. It's called the danger within us. We'll talk some more after a short break. This is FRESH AIR.

(SOUNDBITE OF MUSIC)

DAVIES: This is FRESH AIR, and we're speaking with Jeanne Lenzer. She is a medical journalist. She has a new book called "The Danger Within Us: America's Untested, Unregulated Medical Device Industry And One Man's Battle To Survive It."

You argue in this book that the FDA does a bad job of regulating these devices because they've become heavily influenced, maybe even captured by the industries they regulate. This is a big subject, but briefly, what's the evidence of that? What's happened here, do you think?

LENZER: Well, part of the problem is - is that the FDA commissioner, the lead legal counsel used to be civil servants who came up from within without having to fear political interference. There's a former FDA scientist who told me that decades ago - yeah, they might get a call from a politician now and again and say, hey, what's going on that you're holding up this device approval or that problem? And he said, you know, we'd explain it, and that would be the end of it.

That's no longer the case. We've had a number of instances now, including an episode dubbed Devicegate in which all of the scientists agreed that certain devices should not be approved because they were unsafe and ineffective. And yet the devices were put on the market over the unanimous opinion of their own scientists when politicians made phone calls to FDA superiors. This is really stunning that politics is trumping science. And it's getting worse now with 21st Century Cures Act that was passed in late 2016, which essentially is deregulating even further.

DAVIES: You know, most of us ordinary patients in the world aren't going to do research about medical devices, right? We're going to trust doctors to know what works and what is safe. Broadly speaking, should we?

LENZER: This is a terrific problem. I mean, I have a medical device implanted. I'm very happy with it, but I got to confess. I didn't research it because the truth is we are dependent on the research that comes out of these companies. And that's where I wanted to alert the public that we need to make some structural changes so that we can trust these devices. As you said, we can't individually research them because we don't have the capability to do it. Even if we read the studies that are released, we don't know that we can trust them.

And I'll give you two examples of just how difficult the situation is. One of the people I talk about in the book is a man who was harmed by a hip implant. Well, it turns out that man is also an orthopedic surgeon who specializes in hip replacements, and yet he landed up being poisoned by his hip implant from cobalt that leaked out of the hip and destroyed his muscles and tissues and even caused some degree of heart damage.

Another example is a Medtronic executive that I report on who had a Medtronic device implanted in her spine and suffered just terribly disabling and painful effects from that device. So even people who are insiders and who should know don't really know.

DAVIES: So how do we protect ourselves? What should we do?

LENZER: I don't really think there's any individual way to find out which devices are really safe, except I'll say this. You can go and check the FDA's database and look up the device and see if there are warnings about it. But beyond that, if it's a device that's recommended, many of them do work great. I mean, lives are being saved and transformed in many positive ways. And that's part of what troubles me. I mean, I wouldn't have bothered with this if I didn't feel that there was some merit in the field. Medical devices can be wonderful. What we need is to be able to tell the difference between the ones that don't work and the ones that do work.

DAVIES: You know, we focused a lot on this one case - the vagus nerve stimulator. You write about several others in the book. Are there other devices that are particularly problematic?

LENZER: Yes. The Sprint Fidelis leads that go to defibrillators pacemakers were found to have fractured and cause serious injury and death. And these were implanted in hundreds of thousands of people. And this is one of the problems with devices - is that, you know, what do you do once you're implanted with something that may be dangerous? Having them removed in 15 to 18 percent of people, nearly 1 in 5 people suffered serious adverse events or death when they tried to remove the leads.

Hip implants have leaked chromium and cobalt, and there are other problems. Pelvic mesh - again, a seemingly simple device. It's just mesh after all - surgical mesh. And yet it has grated through tissues like a cheese grater through cheese and caused what's called fistulas - holes between the rectum and the vagina and causing serious pain, infections, hemorrhage. There are all kinds of problems with medical devices that people might want to think about first.

And one of the common things I hear from patients is, you know, now that I think of it, my problem wasn't that serious. So a woman who has a little bit of urinary dribbling when she sneezes or gets excited goes and gets this pelvic mesh put in because a doctor recommends it and then has a lifetime of pain, infections and suffering. So I guess my best advice would be, if you're not certain you really need something, it might be best to wait.

DAVIES: Right. If you take a medication, you can always stop. When you...

LENZER: Yes.

DAVIES: And when you put something inside your body, as you say, the leads may sometimes fuse onto other - create scar tissue and - yeah.

LENZER: And ask if your ER doctors know how to take care of you. I mean, there was one tragic case of a woman with a vagus nerve stimulator who called her sister saying, oh, my God, my VNS is shocking me. I can feel it. It's so painful. I dropped to my knees. And her sister told her, go. Go straight to the ER.

And the young woman who was about 39 years old, a young mother, said, I can't because they don't have the tools to turn this off. I have to wait until my doctor comes in on Monday morning. She didn't get to see her doctor on Monday morning because her 9-year-old daughter found her dead in the bathroom on Sunday night.

DAVIES: You know, this book is powerful. And I could imagine some looking at it and saying, you know, this is too dark a portrait, that there's always risk in treatment and that, you know, people do suffer from conditions that these devices can - are intended to treat and that, you know, you focused on all the problems and maybe given too little attention to people who, you know, are happy with devices that have changed their lives. How would you respond to that?

LENZER: Well, fair enough in terms of my book - not so fair in terms of the total literature out there. And that's why I did focus on the problems because there's a lot of rah-rah information about devices. Everybody's tech-happy and thinks that the newest cutting-edge device must be better than the older device and - when in fact that's not always the case. In fact, when you look at the Sprint Fidelis leads, they were a slight tweak to older leads where they made them somewhat thinner to be more flexible. The problem is, is they were thinner and therefore broke.

So newer isn't always better, and all the excitement about high-tech stuff needs to be moderated with an understanding that these things sometimes cause serious harms. And all I want is for patients to be able to learn the truth so they can make their own assessment about whether they want a device. I want people who have epilepsy to be told the truth about the side effects and downsides as well as the upsides. And that's true for all devices.

DAVIES: Jeanne Lenzer, thank you so much for speaking with us.

LENZER: Thank you. Thank you for having me.

DAVIES: Jeanne Lenzer is an investigative medical journalist. Her new book about implanted medical devices is called "The Danger Within Us." Coming up, David Bianculli reviews the new Amazon series "Electric Dreams" based on the works of Philip K. Dick and the new season of "Black Mirror" on Netflix. This is FRESH AIR.

 

Source: http://wunc.org/post/are-implanted-medical-devices-creating-danger-within-us#stream/0

The broad and diverse medical technology sector by Jonathan Evans

download.jpg

The Medical Technology (MedTech) sector is broad and diverse. There are thousands of products on the market, from wound care dressings, needles and syringes, pacemakers, knees and hips, MRI scanners and blood pressure monitors. The products made are integral to the delivery of modern healthcare and the chances are, we will all need MedTech at some point throughout our lives.

The sector is driven by innovation and underpinned by strict regulation. Products are developed to target a specific need, be it the need to do something faster or more efficiently, cleaner or more cost-effectively.

In the UK alone, MedTech employs close to 100,000 people, generating a collective turnover of £17 billion. Representing this sector is ABHI, the MedTech trade association. ABHI and its members champion the use of safe and effective MedTech, to support health system efficiency and crucially, high-quality patient outcomes. When we consider the advancements in technology, MedTech has the potential to revolutionise the delivery of healthcare as we know it.

In the global context for healthcare, the UK’s differentiating factor is the National Health Service (NHS). As the fifth largest employer in the world, it is comfortably the biggest single-payer health system. It can be a superb test-bed for innovative technologies, yet the system is under great pressure. With an ageing population comes a steady rise in chronic conditions and for some time now, funding for the NHS has not matched the complex health needs of the country.

With tight budgets, there is a natural shift to cost-saving measures. Unfortunately, this often means buying the cheapest available product. However, the cheapest product does not always mean the best overall value. A product that has a longer shelf life, is more durable and of a higher quality, may cost fractionally more per unit, but will have better outcomes for the patient or system. This, in turn, leads to far greater cost savings in the long run. Added to this is the issue of patient safety. When it comes to providing safe and effective solutions to patients, results should be driven, first and foremost, by outcomes.

This view was recently echoed by the former Medical Director of NHS England, Sir Bruce Keogh. In a 2017 interview with the Daily Telegraph, he said too many hospitals were putting cost-cutting ahead of patient safety. “People accept that their disease has risks, they accept that the treatment may carry some risks. What they should never have to accept is that the way we design and deliver our services adds to that risk,” he said.

Added to the NHS’s challenges, the impact of Brexit must be monitored closely. MedTech products, like those in many other sectors, rely on international supply chains. Meaning that products are moved to different countries for material sourcing, manufacturing, packaging and sterilisation. It is not uncommon for a “British” product to have touched several jurisdictions before reaching the market place.

One ABHI member tells us that just one of their products crosses eight borders before completion. For suppliers to be able to move their products across borders, there needs to be practical measures in place to ensure the supply of products to a patient is uninterrupted. Without this, there is a very real danger of delayed supply, which will hit patients the hardest.

For patients’ to be able to access the best in cutting-edge technology, that is not just safe and effective, but also provides genuine value to the system, collaboration will be key. There is a real opportunity for the NHS to capitalise on manufacturing advances. It has the wide-reaching platform to create a collaborative environment where industry and the health system work together to advance the provision of healthcare and safety for patients.

Naturally, there is always room for safety improvements, but the MedTech industry seeks to work closely with patients to better understand the factors which increase adverse events and to develop solutions that are patient-centered. In every step of the pathway, MedTech can help. Prior to admission into a hospital with advanced diagnostic technologies, right the way through to discharge, where patient monitoring devices play a significant role.

 

Source: https://www.openaccessgovernment.org/broad-diverse-medical-technology-sector/41193/

Medical device companies brace for return of Affordable Care Act tax by Jim Spencer and Joe Carlson

download.jpg

During the three years that the government collected a tax on sales of medical devices, Maple Grove's Inspire Medical Systems never turned a profit on its sleep apnea treatments.

CEO Tim Herbert says the company could have had 12 to 15 more employees if that tax money, which helped pay for the Affordable Care Act, had stayed in-house.

Herbert never understood why lawmakers thought it was productive to tax the revenue of Inspire and other device companies that had yet to operate in the black. Now that a two-year suspension of the tax is about to expire, he's more frustrated than ever.


Despite lawmakers' promises, the failure of Congress to kill the device tax has forced Herbert and leaders of hundreds of other Minnesota medical technology companies to adjust budgets and spend money to resurrect or create payment systems for a levy many thought would go away.

With the first installment of the reinstated 2.3 percent device excise tax due Jan. 29, Herbert says he "can't count on" Congress to act.

"We are already committing dollars to prepare to be compliant if [the tax] is reinstated," he said. "We will dedicate staff to [collecting and paying the tax]. And we will change our annual operating budget because we now have to account for those losses."

The same scenario is playing out across the state's massive device sector.

Cogentix is a urology device maker in Minnetonka that is projected to take in about $64 million in revenue in 2018.

"We held out hope that [the device tax] would be repealed," Chief Financial Officer Brett Reynolds said. "Going forward, it could cost us $600,000 or $800,000 [per year]. That's a meaningful number that we would otherwise invest in people, perhaps R&D, potential new business development. I'm sure the money is spent well within the government, but we'd rather put those dollars to work here."

The device tax helps fund the ACA, which provides income-based subsidies credited with helping to expand health care coverage to millions of people.

Several legislative vehicles exist to keep the device tax from coming back.

But only one, a Jan. 19 deadline for a budget resolution, has a set date. Others, such as a bipartisan extension of Medicare benefits or a separate tax extensions package, could come to a vote in January.

U.S. Rep. Erik Paulsen, R-Minn., a long-standing critic of the device tax, said he has the commitment of GOP House Speaker Paul Ryan "to address the issue."

But the promise did not come with a date, and Paulsen was unsuccessful in getting device tax repeal included in a tax reform bill passed in December or in attaching an extension of the current collection moratorium onto other end-of-year legislation. So Paulsen is pushing to have the device tax in the Jan. 19 budget deal.

"My viewpoint is that it is prudent to act sooner than later," said Paulsen, who serves a tech-rich district. "I am hearing from constituent companies that ... mothballed these tax collections for the last couple of years. Now they have to start them up again. It's a time commitment. It's a money commitment. There are companies that weren't even around two years ago that are experiencing this for the first time, and there is confusion."

For trade groups such as the Advanced Medical Technology Association, which includes dozens of Minnesota companies as members, there is a logistics issue: If device tax payments are made before Congress extends the moratorium or repeals the tax, retroactive refunds could be a time-consuming process.

"The Treasury Department is expected to issue guidance that there are no penalties that apply on collections," Paulsen said. "But they do not have the ability to waive the tax under the statute."

The device tax has survived multiple repeal efforts since it was included in the ACA in 2010. Critics, including industry lobbyists, called it a job and research killer.

Proponents said it was a way for the device industry to pay its share of a health reform bill that would add newly insured patients to the device market.

Some argued that companies would simply pass the cost of the tax along to patients in the form of higher device prices. Cogentix CEO Darin Hammers said competition in the med tech sector has often kept that from happening.

"That was the big threat [when the tax was first enacted], is that it would get passed along," Hammers said. "But the problem is, it's a very competitive space so it's difficult to pass it on to the end user."

The tax took effect in 2013 and generated more than $5 billion in federal tax revenue until it was suspended, for two years, at the end of 2015.

The House passed a bipartisan bill, sponsored by Paulsen, to permanently repeal the tax. The bill didn't pass the Senate.

The two-year moratorium was meant to give the House and Senate a chance to work out differences.

Democratic Sens. Amy Klobuchar and Al Franken voted for the tax in 2010 as part of overall health care reform, but both later supported efforts to repeal the device tax.

On Dec. 18, Klobuchar co-wrote a letter with Sen. Joe Donnelly, D-Ind., urging Senate Majority Leader Mitch McConnell and Minority Leader Chuck Schumer to address the device tax before year's end. Klobuchar noted the problems that companies in Minnesota and across the country are experiencing with unexpected expenses related to the possible reinstatement of the tax.

With payments due every two weeks beginning Jan. 29, Klobuchar told the Star Tribune that she will continue "working with Senate leaders on both sides of the aisle to repeal or suspend this tax this month."

Franken resigned from the Senate. His replacement, Tina Smith, said in a statement that she will support repealing the tax.

"I am committed to working with my colleagues in Congress on policies to ensure that our inventors, small businesses, and high-tech workers can continue to innovate," Smith said. "I'll be pressing to find a sensible repeal of the medical device tax in the weeks and months to come."

Paulsen said he will continue to explain to his colleagues that the device tax is different from other ACA taxes that do not have to be dealt with immediately.

"This is the only tax [funding ACA] that is an excise tax," he said. "It is collected on a regular basis where the companies have to figure their sales and send a check to the government."

Herbert believes that approach is not only inappropriate but self-defeating for the country and the device industry generally, especially to smaller companies with good ideas that have not yet grown profitable.

"In essence," he said, "I'm taking investment dollars intended to grow a company and create jobs and create access for patients to new technologies, and using that to pay a tax."

 

Source: http://www.startribune.com/medical-device-companies-brace-for-return-of-affordable-care-act-tax/468705643/

Medical Technology Firms To Trump: GOP Forgot To Ax The Device Tax by Bruce Japsen

A tax on medical device sales under the Affordable Care Act wasn’t included in the Republican-led Congress’ massive $1.5 trillion tax reform package that passed the U.S. House and Senate.

So medical device makers are now taking their case to the White House.

“Unfortunately, while Congress worked with you to advance this major legislative undertaking, they have failed to address a punitive tax that singles out the American medical technology industry, threatening jobs in the U.S. and future innovations for patients, and washing away the benefits of tax reform for our companies,” Advanced Medical Technology Association (AdvaMed) CEO Scott Whitaker said in a letter Wednesday afternoon to President Donald Trump.

“In 11 days, the medical device excise tax is set to be reinstated, meaning a massive tax increase is on its way,” AdvaMed’s Whitaker wrote.

 

The 2.3% tax on medical device sales that is part of the ACA has already been on a temporary hiatus since the beginning of 2016. That suspension is scheduled to expire at the end of the month.

There is legislation in the U.S. House of Representatives that would put the medical device tax on another hiatus. Legislation introduced by Reps. Erik Paulsen (R-Minnesota) and Jackie Walorski (R-Indiana) would suspend the medical device tax for another five years.

But medical device makers are worried legislation to suspend or repeal the device tax will now be put off until next year.

A permanent repeal of the device tax fell victim to the numerous failures to repeal and replace the ACA, also known as Obamacare since Republicans took control of both house of Congress and the White House with the election of Donald Trump.

The Joint Committee on Taxation has said repealing the medical device tax would cost the U.S. Treasury about $20 billion over a decade. Before it was put on hiatus, the IRS collected between $1 billion and $2 billion a year in 2013, 2014 and 2015.

AdvaMed represents hundreds of medical device makers, including Abbott Laboratories, Johnson & Johnson, Medtronic, Stryker and Zimmer.

Device makers say the existing device tax is hurting medical innovation, particularly at small firms, given one-third of device makers have 20 or fewer employees.

"Information drawn from data assembled by the U.S. Department of Commerce showed that the medical technology sector saw a loss of nearly 29,000 jobs while the medical device excise tax was in effect," AdvaMed's Whitaker wrote to Trump. "The onerous effects of this tax have directly impacted a dynamic and innovative sector that provides quality manufacturing jobs, at above average wages, here in the United States."

Source: https://www.forbes.com/sites/brucejapsen/2017/12/20/medical-technology-firms-to-trump-gop-forgot-to-axe-the-device-tax/2/#58c69ffa4642

Cell phones aren’t a public health risk, no matter what California says by Sara Chodosh

Capture.JPG

The California Department of Public Health recently released guidelines for decreasing one's exposure to cell phone radiation. This seems, at first, like a reasonable thing to offer. But the problem with a government body issuing guidelines on how to avoid something is that it implies the thing should be avoided. And there’s no evidence that cell phones are dangerous to your health. Period.

Why would the CDPH want to warn against cell phone radiation if it’s not hazardous? According to CDPH Director Karen Smith, “there are concerns among some public health professionals and members of the public regarding long-term, high use exposure to the energy emitted by cellphones.” That press release goes on to say that some public health official thinks the radio waves emitted “may impact human health,” while also stating that “the scientific community has not reached a consensus on the risks of cell phone use.”

Article Continues Below:

 

How Does A Dyson Swarm Work?

By the year 3100, Earth's skyrocketing population will need a lot of…

We requested that the CDPH send us the information they used to make this decision, and received a lengthy list of links to other government agencies’ positions on the matter. Nearly all of these other agencies have summarized the evidence as showing that cell phones have not been shown to pose a health risk, but that we need to do more long-term studies. It seems that the CDPH has simply drawn a more precautionary conclusion than most of the other agencies based on exactly the same data.

It may be true that certain public health officials think cell phones pose a risk to human health, but it’s misleading to say that there’s no scientific consensus on the subject. There is. The scientific consensus is that cell phones are safe, but that we should still do more research.

This isn’t the first time that California has played it overly safe, to say the least. They also recently decided that glyphosate, or Round-Up, required a label marking it as a possible carcinogen—even though most national and international health organizations agree that glyphosate is safe to use.

 

Source: https://www.popsci.com/cell-phone-cancer-public-health-california#page-2

Analyst Sees 3 Red-Hot Medical Technology Stocks as Huge 2018 Buys by Lee Jackson

5-stocks-under-1-ringgit.jpg

In almost all industries the one thing that continues to drive gains is innovation. Take the car industry as an example: Compare the Model T of 100 years ago to the highest quality Tesla electric car. The changes are stunning, and while 100 years is a long time, the changes are still staggering. One industry where innovation has continued to help make consumers lives better, and in some cases last longer, is medical technology.

Stifel’s medical technology team recently visited with three top companies in their coverage universe. All three are leaders in the specific med-tech silos they occupy and are acknowledged by most on Wall Street as the preeminent firms in their space.

 

The analysts have updated their research on the companies, and all remain Buy rated. While better suited for aggressive growth accounts, they all could supply strong alpha performance in 2018.

Align Technology

This stock has been on fire over the past year and a recent pullback could be offering investors a great entry point. Align Technology Inc. (NASDAQ: ALGN) designs, manufactures and markets a system of clear aligner therapy, intra-oral scanners and computer-aided design and computer-aided manufacturing (CAD/CAM) digital services for use in dentistry, orthodontics and dental records storage in the United States and internationally.

The company’s Clear Aligner segment offers Invisalign Full, a treatment used for a range of malocclusion. Its Invisalign Teen treatment addresses orthodontic needs of teenage patients, such as compliance indicators, compensation for tooth eruption and six free single arch replacement aligners. And its Invisalign Assist treatment is for anterior alignment and aesthetically-oriented cases.

The Scanners and Services segment offers iTero Scanner, a single hardware platform with software options for restorative or orthodontic procedures, and Restorative software for iTero, a software for GPs, prosthodontists, periodontists and oral surgeons. It also provides Orthodontic software for iTero, a software for orthodontists for digital records storage, orthodontic diagnosis, Invisalign digital impression submission and for the fabrication of printed models and retainers.

Stifel remains positive on the shares and its research report noted this:

We continue to believe that International, Teen and the non-comprehensive Adult market offer Align significant long-term growth opportunities. Internationally, the company expects to grow through breadth and depth. Align’s CFO John Morici spoke to ongoing traction in China, Japan and EMEA, while certain Greenfield markets (India and Brazil) should play a bigger role in coming years. Furthermore, Morici highlighted that Align’s global supply chain effort is just underway, which should further aid international growth in coming years.

The Stifel price target for the shares, which have traded in a stunning 52-week range of $88.56 to $266.41, is $265. The Wall Street consensus price objective is $273.73, and shares closed on Friday at $233.55.

Edwards Lifesciences

This company pioneered the artificial heart valve, and it could be poised for big growth. Edwards Lifesciences Corp. (NYSE: EW) provides products and technologies to treat structural heart disease and critically ill patients worldwide. The company offers transcatheter heart valve therapy products, comprising transcatheter aortic heart valves and their delivery systems for the nonsurgical replacement of heart valves.

 

Source: http://247wallst.com/healthcare-business/2017/12/18/analyst-sees-3-red-hot-medical-technology-stocks-as-huge-2018-buys/

NASA Funds Flight for Space Medical Technology on Blue Origin by Space Daily

Blue Origin successfully launched its New Shepard reusable space vehicle on Dec. 12 carrying a medical technology that could potentially treat chest trauma in a space environment.The New Shepard reusable vertical takeoff and vertical landing space v…

Blue Origin successfully launched its New Shepard reusable space vehicle on Dec. 12 carrying a medical technology that could potentially treat chest trauma in a space environment.

The New Shepard reusable vertical takeoff and vertical landing space vehicle was launched with the experimental technology from Blue Origin's West Texas launch site. In addition to NASA funding non-government researchers to fly payloads, Blue Origin is a Flight Opportunities program launch provider for government payloads. The Flight Opportunities program, is managed under NASA's Space Technology Mission Directorate (STMD).

"This flight marks the first of many Flight Opportunities' flights of payloads with Blue Origin," said Ryan Dibley, NASA Flight Opportunities campaign manager for Blue Origin.

"New Shepard brings new capabilities to the program. This launch platform allows for larger payloads, provides lower launch accelerations, and maintains a sealed pressure environment."

With NASA funding to support the flight cost, the Evolved Medical Microgravity Suction Device technology was developed by Charles Marsh Cuttino and his team at Orbital Medicine, Inc. in Richmond, Virginia.

The device could potentially assist in treating accidents such as a collapsed lung where air and blood enter the pleural cavity. The payload was constructed in collaboration with the Purdue University of Aeronautics and Astronautics in Indiana.

Currently astronauts and cosmonauts have to return to Earth quickly for medical treatment should an incident arise with chest trauma on the International Space Station. Collapsed lungs are treated on Earth with gravity dependent collectors that will not work in space.

"My hope is that in the future, this type of medical device will be able to save the life of an astronaut, to continue their mission of exploration," said Dr. Cuttino.

"These types of medical treatment options could be required to explore the Moon and Mars."

The new technology has a suction system that collects the blood in microgravity and allows for the lungs to continuously inflate as well as store blood for transfusion. The device also has a pneumothorax simulator, which simulates an injured person and shows how the device removes the air and blood to promote healing.

Orbital Medicine's suction device technology was selected in Nov. 2015 under a NASA Research Announcement: Space Technology Research and Development, Demonstration and Infusion, or Space Technology REDDI-2015. The device has already flown on parabolic flights with past program funding.

Through the Flight Opportunities program, STMD selects promising technologies from industry, academia and government for testing on commercial launch vehicles. The Flight Opportunities program is funded by STMD, and managed at NASA's Armstrong Flight Research Center in Edwards, California.

STMD is responsible for developing the crosscutting, pioneering, new technologies and capabilities needed by the agency to achieve its current and future missions.

Source: http://www.spacedaily.com/reports/NASA_Funds_Flight_for_Space_Medical_Technology_on_Blue_Origin_999.html

Return Of Medical Device Tax Causing A Stir by Matt Murphy

0915_mri-scan-1000x786.jpg

The failure of Republicans in Congress this year to repeal the Affordable Care Act means that a controversial tax on medical device sales will return in 2018 unless legislators intervene in the next couple weeks, putting a major Bay State industry on edge.

The tax, which was included in the 2010 health care reform law as a way to help pay for an expansion of Medicaid, puts a levy of 2.3 percent on devices like X-ray and MRI machines, surgical instruments and pacemakers. After a brief suspension, the tax is set to be reinstated in January.

Many members of the Massachusetts delegation have been vocal in their opposition to the medical device tax since its inception, but on Wednesday Republican Beth Lindstrom sought to make it an issue in her U.S. Senate campaign by calling out U.S. Sen. Elizabeth Warren for not pushing repeal during the Senate tax reform debate.

"The medical device industry produces a constant stream of life-saving innovations. As Senator, one of the first things I'll do will be to file a repeal bill and work with colleagues on both sides of the political aisle to pass it," Lindstrom said in a statement.

The medical device industry in Massachusetts, according to the Massachusetts Medical Device Industry Council, accounts for about 480 firms and 21,000 jobs. Seventy percent of those companies MassMEDIC President Tom Sommer said, have fewer than 10 employees and could struggle to comply with and absorb the tax.

"The next 24 to 72 hours are going to be critical to efforts to repeal or suspend this tax further," said Sommers, who took part in a conference call Wednesday on the issue with the national Advanced Medical Technology Association.

With House and Senate leaders in Washington arriving at a compromise Wednesday on tax reform, Sommers said the hope is that Congress will turn its attention in the final weeks of the year to other issues that must be dealt with, including a reauthorization of the Children's Health Insurance Program.

Lindstrom wrote a letter to Warren and U.S. Sen. Edward Markey in October during the tax reform debate on Capitol Hill urging them to use that as an opportunity to eliminate the tax for good, but repeal did not make it into either the House or Senate tax bills.

She blamed Warren for being "too busy grandstanding her opposition to lower taxes."

A spokeswoman for Warren said the senior Democratic senator opposed the Republican tax bill, as did all other Democrats in the Senate, making it an inappropriate vehicle to push for other reforms.

Warren has long supported repeal of the medical device tax, though she has favored, like many other Democrats, ensuring that the lost revenue would be replaced.

"When Congress taxes the sale of a specific product through an excise tax, as the Affordable Care Act does with medical devices, it too often disproportionately impacts the small companies with the narrowest financial margins and the broadest innovative potential. It also pushes companies of all sizes to cut back on research and development for life-saving products. With an appropriate offset, we can repeal the medical device tax without cutting health care coverage for millions of people or forcing Americans to fight the whole health care battle all over again," Warren wrote in a 2012 op-ed during her first campaign for Senate.

The Congressional Budget Office estimates that elimination of the medical device tax would cost the Treasury $24.4 billion over a decade.

After the tax was collected in 2013, 2014, and 2015, it was delayed by Congress and is set to resume on Jan. 1.

House Ways and Means Chairman Kevin Brady announced a package of bills introduced this week to provide relief from Obamacare taxes, including the "Cadillac tax" on high-cost insurance plans. One bill sponsored by Rep. Erik Paulsen of Minnesota would suspend the medical device tax for another five years.

It's possible that one or more of those proposals could be attached to an end-of-year spending bill or CHIP reauthorization, industry insiders believe.

"We'd like the permanent repeal, but suspending the tax for another five years would be an important first step to dealing with the uncertainty in the industry right now," Sommers said.

Because of the way the device tax is structured, Sommers said that without a repeal or suspension of the tax, medical device firms would have to make a first payment the second week of January based on estimated sales going forward. This requirement, he said, particularly hurts small device manufacturers and start-ups that don't have a lot of capital.

"We'll see what we saw during the years the tax was in place. Companies will be looking very carefully at their expenditures in research and development and investments in innovation. They'll be looking at head count and other ways to slim down to account for the 2.3 percent that's taken off the revenue line," Sommers said.

Lindstrom's campaign said that from 2005 to 2010 prior to passage of Obamacare, employment at Massachusetts medical device companies grew by 15 percent, and held steady during the recession. However, employment fell by 9 percent from 2011 through 2016.

Sommers said MassMEDIC doesn't have precise numbers on the numbers of jobs lost following passage of the Affordable Care Act, but said he knows anecdotally that layoffs attributed to the tax did occur.

U.S. Reps. Seth Moulton of Salem, Steve Lynch of Boston and William Keating of Bourne have been active in pushing for repeal of the device tax, according to MassMEDIC, while others in the delegation have also been supportive.

Warren voted for a repeal amendment in 2013, and she also backed legislation filed by Moulton in 2015 to eliminate the tax, according to an aide.

 

Source: http://www.wbur.org/commonhealth/2017/12/14/medical-device-tax

Under New Bill, Medical Device Tax Might Vanish, But Only Temporarily by Bruce Japsen

A controversial tax on medical device sales under the Affordable Care Act could be suspended again rather than disappear permanently under new legislation emerging in the Republican-led Congress.The 2.3% tax on medical device sales that is part of t…

A controversial tax on medical device sales under the Affordable Care Act could be suspended again rather than disappear permanently under new legislation emerging in the Republican-led Congress.

The 2.3% tax on medical device sales that is part of the ACA has already been on a temporary hiatus since the beginning of 2016. That suspension is scheduled to expire at the end of the month.

But new legislation emerging in the U.S. House of Representatives would put the medical device tax on another hiatus. Reps Erik Paulsen (R-Minnesota) and Jackie Walorski (R-Indiana) said the proposed legislation would suspend the medical device tax for another five years under a new bill introduced Tuesday.

“As we continue working toward a patient-centered health care system, Ways and Means Republicans are taking action to provide targeted relief from taxes that stand in the way of affordable health care, innovative treatments, access to medications, more jobs, and bigger paychecks for hardworking Americans,” House Ways and Means committee chairman Kevin Brady (R-Texas) said Tuesday.

 

A permanent repeal of the device tax fell victim to the numerous failures to repeal and replace the ACA , also known as Obamacare, since Republicans took control of both Congress and the White House with the election of Donald Trump. A device tax repeal was included in most failed Obamacare replacement bills.

The Joint Committee on Taxation has said repealing the medical device tax would cost the U.S. Treasury about $20 billion over a decade. Before the medical device tax was put on hiatus, the IRS collected between $1 billion and $2 billion a year in 2013, 2014 and 2015.

It remains unclear what piece of legislation the device tax suspension bill will be attached to, Congressional committee staffers say. Several legislative efforts linked to healthcare are wending their way through Congress in these last three weeks of the year that include: funding of the government; tax cuts and renewal of the Children’s Health Insurance Program, also known as CHIP.

“A five-year suspension is an important first step to provide medical technology innovators with confidence that this tax will not go back into effect,” Advanced Medical Technology Association (AdvaMed) CEO Scott Whitaker said Tuesday. “With time running short, we urge Congress to adopt this suspension immediately.”

AdvaMed represents hundreds of medical device makers, including Abbott Laboratories, Johnson & Johnson, Medtronic, Stryker and Zimmer Biomet. Device makers say the existing device tax is hurting medical innovation, particularly at small firms, given one-third of device makers have 20 or fewer employees.

“During the current suspension, medtech companies have been able to reinvest millions that otherwise would have been lost to the tax into new jobs, capital improvements and R&D to fuel the next generation of life-changing technologies for patients.” AdvaMed’s Whitaker said. “We are committed to continuing this reinvestment in innovation if the tax is suspended on a long-term basis going forward.”

 

Source: https://www.forbes.com/sites/brucejapsen/2017/12/13/rather-than-repeal-medical-device-tax-may-be-suspended-again/#497a71e31c57

Using Digital Health Technology to Avoid Medical Mistakes by Staff Writer

Medications are one of the most critical parts of treating countless injuries, illnesses, and chronic conditions. They are prescribed based on the best course of treatment for the patient’s particular situation, so it is essential that the patient i…

Medications are one of the most critical parts of treating countless injuries, illnesses, and chronic conditions. They are prescribed based on the best course of treatment for the patient’s particular situation, so it is essential that the patient is given the correct pharmaceutical in the correct way for optimum results.

It is bad enough to think that a medical error gives the patient no positive change, but it is even worse when such an oversight causes a negative impact on the patient. For that reason, it is essential that everyone involved in patient care has foolproof systems and technologies for ensuring that medications and other interventions are properly provided to patients.

This is a greater challenge than one might initially think. Although patients are seen individually, the medical professionals who administer medications and other therapies are dealing with a significant overall patient load. No matter how intimately familiar they may be with a given patient’s condition, it can be very easy in the hectic pace of a hospital or clinic to get confused and make a mistake. Sadly, it happens quite often.


Healthcare staff are often operating with few verification procedures. Instructions are provided for the correct dosages and medications for the patients, but those who administer them often work alone from that point on. Despite the best efforts of hospitals to encourage loved ones to keep an eye on the care given to patients, families and even the patients themselves frequently don’t know what the patient’s medication should look like. Other patients are unconscious and/or alone, so it is typically up to the staff member alone to get things right.

Rather than attempt to memorize or guess at pill types, they need to utilize tools like a pill identifier that gives reliable information so that a floor’s worth of medication can be properly verified quickly to reduce the chances of a mistake. Should any type of interruption take place that disrupts the flow of their medication deliveries, they can quickly look up each medication and be sure that their work can be picked up right where it was left off.

Technology is no stranger to health care. After decades of confusion caused by illegible or smudged handwritten prescriptions, many are now handled electronically so that the information can be accurately and securely transferred from practitioner to pharmacist with no risk of errors or interception by abusers. This also eliminates the need for the complicated system of watermarked pads and their theft by pill abusers.

Of course, the role of technology in healthcare isn’t confined to the here-and-now factors. It also involves patient history. Electronic health records (EHRs) are much safer and more compact than old paper records, reducing space and operating in a more eco-friendly way.

Additionally, they are much easier to manage. Instead of constant duplication, faxing, shipping, and mailing, records can be sent clean and secure via email, arriving in a fraction of the time and going to as many recipients as necessary. Instead of an ailing patient having to carry a bundle of envelopes to a specialist, the records will arrive first. Not only does that make things easier for the patient, it also increases the time available for the specialist to review things before actually seeing the patient.

Gone are the days when cumbersome books and endless scribbled notes were necessary to prescribe and administer drugs correctly. Today there are countless technological assets available to medical personnel to provide support when their time, work load, and memory simply can’t keep up. Together, these skilled workers and their reliable technological tools are building a healthier tomorrow for all of us.

 

Source: http://hitconsultant.net/2017/11/14/using-technology-avoid-medical-mistakes/

DIGITAL HEALTH BRIEFING: Fitbit data could predict readmission rates — Humana's new digital medication management tool — Interoperability complicates Aurora-Advocate merger by Laurie Beaver

FITBIT DATA AIDS RESEARCHERS IN UNDERSTANDING SURGERY RECOVERY: Fitbit data can help researchers and doctors predict the risk of 30- and 60-day readmission after surgery for cancer patients, according to a study published in the Annal…

FITBIT DATA AIDS RESEARCHERS IN UNDERSTANDING SURGERY RECOVERY: Fitbit data can help researchers and doctors predict the risk of 30- and 60-day readmission after surgery for cancer patients, according to a study published in the Annals of Behavioral Medicine. Patients who exercised more than others had a lower readmission risks following cancer surgery. This was the first clinical study to link Fitbit-tracked footsteps to readmission rates.

Researchers are keen to use Fitbit data in their studies. More than 500 studies have been published using Fitbit device data since 2012. And almost half of those were published in 2017. Moreover, in clinical trials, 83% of trial participants are provided with a Fitbit device.

The ability to provide meaningful insights for doctors and researchers could bolster the value proposition of Fitbit devices and other wearables. Wearable devices, which include activity trackers and smartwatches, can provide near-continuous data on the lifestyle of patients who wear them. Aside from post-surgery patients, Fitbits can also be used to help monitor patients with chronic illnesses, which could help to lower costs associated follow-up care, and unnecessary readmissions. If researchers can show that wearable data is medically useful, it will make buying these devices more compelling for consumers as well as health organizations that are considering providing them to their patients. 

 

 

Fitbit is not the only company thats looking to use their wearables in digital health. Apple, for instance, recently began the Apple Heart Study with Stanford Medicine. And in April, Verily, Alphabet’s life sciences business, unveiled a health tracking watch built specifically for research purposes. These companies are all vying for a piece of the global healthcare wearables market, which is projected to be worth more than $612 billion globally by 2024, according to Grand View Research.

BI Intelligence

HUMANA INTRODUCES A DIGITAL MEDICATION MANAGEMENT TOOL:Humana, the insurance provider, has introduced a digital tool to aid patients in managing their medications. The tool, which is called RXMentor, automatically pulls in claims data to build out a list of medications users are currently or have previously used. Patients can then share this up-to-date list with providers, track their medications, and make notes about specific adherence instructions. Humana is likely hoping this new tool will improve the health of its members by increasing the likelihood of medication adherence — it's part of its broader goal of having its members become 20% healthier by 2020. Nearly 75% of Americans fail to take medication as directed causing roughly $300 billion a year in additional visits to the doctor, emergency room, and hospital, according to the American Heart Association 

EHR INTEROPERABILITY TO PLAY A BIG ROLE IN AURORA-ADVOCATE MERGER: A potential merger between Advocate Health Care and Aurora Health Care would likely involve some level of integration of the three separate electronic health record (EHR) systems, according to FierceHealthcare. The merger would create a 27-hospital healthcare system in the US, with an estimated annual revenue of $11 billion. However, it's not clear whether the newly formed company would retain the three EHR systems it currently uses or choose one. Aurora currently uses Epic, while Advocate uses Cerner and Allscripts.

CEDAR GETS $13 MILLION IN FUNDING FOR ITS SMART BILLING SOLUTION. New York City-based Cedar, a medical billing startup, raised $13 million in Series A funding to build upon the firms billing services, according to VC News Daily. Cedar gathers patient data, such as billing history, engagement level on different communication methods, and demographic information. It then uses this data and machine learning to give providers a smart billing solution with improved methods of communication and payment in order to engage patients. Early tests have shown that Cedar's solution can be a useful tool — on average, providers saw a 22% increase in collections, a 33% reduction in accounts receivable days, a 62% increase in self-serve payments, and 90% patient satisfaction. And given that patient payments represent a significant portion of provider revenue — patient payments account for 35% of revenue — personalized data-driven solutions like Cedar's that can help providers collect payments are likely to be adopted. 

 

Source: http://www.businessinsider.com/digital-health-briefing-fitbit-data-could-predict-readmission-rates-humanas-new-digital-medication-management-tool-interoperability-complicates-aurora-advocate-merger-2017-12

3 Ways to Design User-Friendly Health Technology by

download.jpg

GE Healthcare realized it had an issue with its MRI machines when it learned that 80 percent of pediatric patients needed to be anesthetized to undergo MRI scans. If the vast majority of your customers are so afraid of your product that they have to be unconscious to endure it, you may want to rethink your design, said Tom Kelley, general manager of IDEO, an international design and consulting firm.

GE reimagined its MRI machines with the GE Adventure Series, which makes them look like “a ride at Disneyland,” such as a pirate ship or a rocket, Kelley said. The strategy worked: The rates of anesthesia for pediatric MRI patients dropped to less than 10 percent.

GE was able to radically change its customers’ experience by embracing empathy and altering how customers interacted with its technology, a lesson all organizations, large and small, can take to heart, said Kelley during a keynote speech at the CDW summit, “Transforming the Customer Experience with Digital Modernization,” held in New Orleans in September.

As health technology marches forward, with health apps and mobile health tech entering the space at a rapid pace, Kelley laid out three key design principles that can continue to enhance the patient and provider experience with health technology and apps. Organizations, he said, need to make their technology human-centric, experiment continuously to determine how patients want to use technology and tell a simple story to their customers. For this, health IT companies can look outside of the healthcare realm and into other industries that are infusing elements of these user-centric best practices into design and development.

1. Make Health Technology Human-Centric

A critical element to transforming the user experience is to design products and services with the patient and clinician in mind. That may seem obvious, but it’s often difficult to achieve.

Kelley noted that GE did not change the underlying technology of its MRI machines. The company instead altered the user experience. GE “saw a problem that no one else was really trying to solve” and “solved it really well,” he added.

That approach can be applied to many aspects of other health technology design. Evan Carl, general manager of North America partnerships at Kony, which helps organizations design enterprise mobile applications, said that in today’s digital world, many companies want to “build a closer connection” with their end customers.

At the summit, Carl pointed to companies outside of the health industry that are using mobile technology to improve their relationships with customers. By way of example he cited KMC Controls, which makes commercial-grade industrial controls for HVAC and building automation systems. KMC enlisted Kony to improve the setup process for one of the company’s devices, which was “pretty ugly” and complicated, according to Carl.

Kony built an app for KMC that allows customers to automatically set up one of the devicessimply by placing a smartphone on top of the product’s box.

“They found that there was a 75 percent reduction in time on the front end” to set up the devices, Carl said. That enhances the customer experience and delivers a more pleasant interaction with KMC, he added. mHealth companies or developers can look to provide similar ease of use to clinicans or patients as they delve into the world of development.

2. Constant Experimentation Paves the Way to User-Centric Design

Kelley noted that by continuously revising an idea and incorporating customer feedbackthroughout an experimental or testing stage, healthcare organizations and mhealth companies can more closely align their products and services to how patients and clinicians want to use them. This can transform the user experience by reducing user frustration and giving patients and providers the features they actually want.

He highlighted Ankit Gupta and Akshay Kothari, creators of the news app Pulse, as designers who used continuous experimentation to achieve technology success. Gupta and Kothari designed Pulse for Apple’s iPad after the first version of the tablet came out. Initially, the app was so messy it was almost unusable. After a few weeks of tinkering, test customers found the app so useful that they wondered if it came installed on every iPad.

Gupta and Kothari told Kelley they were making 100 updates to their software every day as a result of interactions with customers. They made more than 1,000 revisions to their software before they released 1.0 and got customers signed up. Eventually, Pulse got 30 million customers, and in 2013, LinkedIn acquired it for $90 million.

The success came from all the prototypes Gupta and Kothari made. “They did more experiments than anyone,” Kelley said. By experimenting and testing constantly, healthcare organizations and mhealth developers pursuing their own healthcare apps can figure out more quickly how patients and clinicians want to use their services, and then design features and functionality around those desires. In the end, this process increases satisfaction because organizations are giving users what they want.

3. Drive Your Health Product Experience with Compelling Stories

The third key to transforming the customer experience is the ability to “leverage the power of storytelling” to enhance the experience. A key element of stories, he said, is to make them simple: “What is the distilled essence of your story?”

The ability to tell stories to customers in a simple way allows healthcare organizations to convey their core values and the benefits of their products more easily. That, in turn, gives users a greater appreciation for what those benefits are.

“What's your message that you want people to listen to and remember and tell their colleagues?” Kelley said. “If you find your story, it will carry your message.”

When Kelley joined IDEO, it seemed to him that most of the company’s employees were engineers. “We thought that there’s data and there’s stories, and stories are only useful when you’ve got no data at all. Also known as bull,” he said. “We flipped 180 degrees, and we now believe that stories are how you make your data come to life.”

At Apple, simplicity in design is a key value, along with surprising and delighting customers. These values permeate Apple culture, including how sales associates interact with customers, explains one Apple executive.

Two million sales associates worldwide at companies such as CDW, AT&T, Best Buy and Verizon sell Apple products even though they are not Apple employees. Partner sales associates are responsible for explaining how products work and engaging with customers in a way that represents the Apple brand effectively. Apple’s SEED app provides partner sales associates with technical and sales resources, news and tips about Apple products. “We wanted them, in a down moment, when there were no customers on the floor, to be able to grab the app and learn something in 60 seconds and then have a customer approach them and maybe weave that right into their conversation,” according to the Apple executive.

The native iOS app gives Apple a way to efficiently deliver up-to-date product information to its retail partners. In turn, those sales associates can use that information to tell a simpler, more effective story to customers about Apple’s products. They also can answer customers’ questions more easily, which improves the customer experience.

The app recently passed a billion minutes of use, even though it’s only been out for about two years. “So, it’s huge scale. But when we solved for it, we were thinking very much about a group of customers that were going to be the consumers and the impact that those customers and salespeople would have upon the end customers,” the Apple executive said. “I think it's a good proxy for the type of work you should be thinking about relative to customer experiences.”

 

Source: https://healthtechmagazine.net/article/2017/12/3-ways-design-user-friendly-health-technology

Medical technology is a driver of health and wealth by Bill Doherty

Bill Doherty is the vice-president of Cook Medical EMEA and managing director of Cook Medical Ireland.Doherty joined Cook Medical Ireland as its first employee in 1994. Prior to this, he held senior management positions with Atari, Digital Equi…

Bill Doherty is the vice-president of Cook Medical EMEA and managing director of Cook Medical Ireland.

Doherty joined Cook Medical Ireland as its first employee in 1994. Prior to this, he held senior management positions with Atari, Digital Equipment Corporation and EG&G Electro Optics.

Cook Medical began operations in Ireland in 1996 and will celebrate 22 years in Limerick in 2018. The company employs approximately 900 people at its plant in Limerick and supports more than 600 field-based European staff.

Doherty recently spoke about global marketing strategy at the Medtech Rising conference in Galway, which concludes today (7 December).

Describe your role and what you do.

As executive vice-president, my role is to coordinate Cook Medical’s business in Europe, Middle East and Africa (EMEA). Like many organisations, Cook Medical has a matrix structure, and I spend a lot of my time ensuring that the various functions and divisions are coordinated, EMEA specific issues are addressed at corporate level, and horizon scanning to try to identify threats and opportunities to the business.

Another focus of my role is participating in local and international forums to discuss and influence the future of the medtech industry. As EMEA is made up of multiple jurisdictions, there is also often a need for country-specific solutions. I spend a lot of time travelling as I believe communicating with employees, customers and other stakeholders is very important, and gives me a view of the business from different perspectives.

How do you prioritise and organise your working life?

I try to follow a structured working day – however, it’s important to be flexible and accessible. I am not driven by deadlines and appointments but I try to find time to think longer-term and to meet with others to understand their issues as well as soliciting their advice and input. I have always adopted a hands-off approach to management, and believe in hiring strong people and letting them manage their areas of responsibility without too much interference.

What are the biggest challenges facing your sector and how are you tackling them?

I think the greatest challenge for the medtech industry is to demonstrate that medical technology is a driver of health and wealth, and not simply a cost for healthcare systems. As populations age, it is becoming more difficult and expensive for governments to provide high-level healthcare for all its citizens. The challenge for the industry is to demonstrate better clinical and economic outcomes for patients and for healthcare systems globally. Medtech has a role to play in partnering with healthcare systems to help drive efficiencies in areas such as logistics, procurement and IT.

A more immediate challenge for the sector is the new European medical device regulations, which will bring substantial changes to the European regulatory environment and will add a new level of complexity to placing devices on the market in Europe. While some of the new regulations are to be welcomed, I am concerned that other provisions could stifle innovation or, at the very least, make it very onerous for start-ups to survive through to commercialisation. This could also have the effect of diverting venture capital away from medtech due to the progressively longer lead times and increased hurdles to bring a new product to market.

What are the key sector opportunities youre capitalising on?

Like many in the sector, I see emerging markets as an area of growth but also one with different challenges and opportunities. Many emerging markets have complex supply chains with multiple layers, which results in reduced efficiency.

There is a trend of diverging regulations in these markets, with some larger emerging markets setting up regulatory environments that favour local manufacturers. While there are many challenges in these markets, there is a growing population who want better quality healthcare and can afford to pay for it, which ultimately leads to increased opportunities for the medtech industry.

We are also seeing a move towards personalised healthcare. This is still very much a developing area but there are opportunities for medtech to offer patient-specific solutions.

What set you on the road to where you are now?

Fate or accident – I’m not sure, but I happened to be in the right place with the right experience when Cook Medical decided to set up an operation in Ireland. It has been a tremendously rewarding journey and there is no doubt that those of us who work in medtech are extremely fortunate and get a great buzz from seeing how our products help to improve and save lives.

What was your biggest mistake and what did you learn from it?

I recall in my early days being captivated by a very eloquent physician who convinced me to work with him to develop a new product. After almost a year’s work, we launched this product and didn’t sell a single unit. It wasn’t that the product didn’t work but, as it was an aide to using an existing product, customers weren’t willing to pay for it and expected it for free. I learned that good ideas can come from anywhere and that it’s important to separate the idea from the person, take the idea on its own merits and eliminate personal bias. This is where market research is invaluable.

How do you get the best out of your team?

I try to empower my team and then get out of the way. I see my role as setting direction and making sure that we continue to have a strong culture. While we are a large company, we are still a family-owned business and try to maintain family values in a global world, which means we look out for one another and for our communities. From a business perspective, this means ensuring that we put patients at the centre of our entire decision-making process.

STEM sectors receive a lot of criticism for a lack of diversity in terms of gender, ethnicity and other demographics. Have you noticed a diversity problem in your sector? What are your thoughts on this and whats needed to be more inclusive?

There is undoubtedly a gender imbalance in STEM and this is a huge cost to industry and society in general. I think there are numerous reasons for this imbalance but, certainly, a lack of female role models and societal norms are among them. I believe it is in society’s interest to try to address this imbalance in business, education and in the home.

Many of Cook Medical’s highest-achieving engineers are women. I would encourage girls setting out on their career path to consider engineering. It’s a rewarding and varied job that has real-world applications.

Who is your role model and why?

I admire people who are themselves and enjoy what they do. I don’t have a particular role model but I admire people like Richard Branson – he has enthusiasm for his work, he doesn’t take himself too seriously and he is not afraid to do what others might regard as silly in his personal life. I think it’s important to take business seriously but to allow time for the frivolous things in our personal lives.

What books have you read that you would recommend?

I primarily read for relaxation and tend to favour historical novels rather than business books. One book that has always fascinated me is The Prince by Niccolò Machiavelli. It’s a tough but rewarding read and gives great insight into power and especially what people will do to achieve and keep it. My favourite author is Bernard Cornwell; I really enjoyed his most recent series, The Saxon Stories, which depicts the struggle between the Saxons and Vikings for control of England.

What are the essential tools and resources that get you through the working week?

I remember business with telex and fax machines so, from a technology perspective, email and WebEx have become indispensable, not to mention mobile phones. I’m fortunate in that I work with a large company, so I have a lot of support.

 

Source:https://www.siliconrepublic.com/companies/bill-doherty-cook-medical

Why we need to fix the broken technology pipeline for digital medicine now by Neil Carpenter

When it comes to health information technology, innovative ideas and companies abound. Downstream improvements in outcomes or costs of care resulting from these innovations, however, have to date been underwhelming.To illustrate this observation, th…

When it comes to health information technology, innovative ideas and companies abound. Downstream improvements in outcomes or costs of care resulting from these innovations, however, have to date been underwhelming.

To illustrate this observation, there is no better example than the limited results yielded by the massive investment in electronic health records (EHRs). Another can be found in the $28.7 billion consumer wearable technology market. A recent randomized controlled clinical trial found that individuals using wearables lost less weight over 24 months than those making lifestyle changes alone.

This finding is disappointing, but unfortunately not unusual — despite generating such excitement and investments in these innovations, less-than-optimal or even negative outcomes make it clear that we have yet to fully ascertain HIT’s potential.

Some may attribute this underperformance to the general complexities and attributes of the healthcare sector, but we, as members of the Network of Digital Evidence (NODE), disagree. One need only to look to the drug and device industries to see examples of far more mature and effective, albeit imperfect, processes that have served as guides for countless innovations from development through to scaling and implementation.

An unwieldy HIT ecosystem (or innovation pipeline), especially related to digital medicine, has developed, one in which innovators create products and then scramble to navigate the complex and opaque needs and buying processes of health systems.

The end consumers may not be familiar with a particular innovation, but they can be assured that the drug or device in question has passed a rigorous FDA-led evaluation. There are no such guidelines or evaluations to serve/for the HIT innovation community.

Medical institutions, meanwhile, struggle to sort through the vaporware and correctly identify the legitimate and promising innovations in digital medicine.

Despite major investments in HIT, drug and device development appear to dramatically outpace that of HIT innovation — why? This may ultimately be due to the maturity of the innovation pipeline across those three segments of the healthcare system. The drug and device pipeline is far more standardized, academic, and regulated than that for HIT, and it is this level of sophistication that enables a consistent production of novel drugs and devices.

It is clear that HIT must develop a comparably evolved pipeline; only then will this sector stand a chance of enjoying a steady, reliable stream of implementable innovation.

 

Source: http://www.healthcareitnews.com/blog/why-we-need-fix-broken-technology-pipeline-digital-medicine-now

5 Digital Health Innovation Trends That Will Matter in 2018 by Fard Johnmar

In December 2016, many were suggesting that wearables were dead. Fitbit’s stock price was rapidly dropping. Apple Watch sales had declined for two consecutive quarters and Pebble had just been acquired in a fire sale.

What a difference a year makes. Today, Apple Watch is poised to become the world’s best selling wearable. And, the market is quickly diversifying as hearables (once again led by Apple) and clinical wearables gain importance.

The lesson is clear. As we look toward 2018, it’s more important than ever to focus on the underlying fundamentals of the global digital health market rather than individual technologies that will undoubtedly rise and fall as consumer/enterprise attention waxes and wanes.

 

To help you focus on the big picture, I present five digital health innovation trends that will matter in 2018, as outlined in the infographic (and explained in detail) below.  These trends were identified via examination of our database of 4 million + data points re: digital and emerging technologies and my ongoing analysis of digital health trends for Enspektos’ clients.

1. Policies and Regulations Drive and Threaten Innovation

While the U.S. Food and Drug Administration pushes to speed digital health innovation, uncertainty persists re: the impact of net neutrality’s repeal and the EU’s General Data Protection Regulations.

 

As the Innovation Map above illustrates, the U.S. Food and Drug Administration made moves in 2017 to provide certainty and a (potentially) more permissive regulatory environment that should help speed digital innovation in the U.S. Because the will be FDA pursuing its digital health innovation action plan in 2018, there is no reason to believe this will change.

However, there are other regulatory and legal headwinds that will cause uncertainty during 2018. The first is the repeal of net neutrality rules, which will give major telecoms more control over how content is distributed and whether companies must pay more to acquire and deliver data and information. Some of the potential negative impacts of net neutrality’s repeal on digital health include:

– Fees for Access to Stored Data Could Increase: Health organizations are already paying fees to store EHR data, and these costs could increase if they are charged higher rates to access this information.

– Remote Patient Management Could Become More Difficult: Patients who need reliable, high-speed Internet for remote monitoring, teleconsults and service delivery could face bottlenecks.

The second issue is the upcoming EU-wide General Data Protection Regulation, which mandates significant changes to how the personal digital data of EU citizens is collected and managed. Importantly, the rules apply even to organizations that are not operating in EU countries — if they collect or have access to the personal data of any EU citizen. There is uncertainty about how individual EU countries will implement the legislation and the Personal Connected Healthcare Alliance fears that “Member States could adopt substantially different rules … leading to a fragmentation … Of the nascent European market in digital health …”

Companies in health technology and digital health should be watching (and planning for) these legal/regulatory issues actively throughout 2018.

2. Patient-Generated Data Comes of Age

The rise of passive biometric and digital tracking technologies, improved data analysis tools and related innovations transform patient-generated data into a high-value resource.

For much of the last decade patient-generated data had a poor reputation. Although many pressed for its integration into health and medical care, lack of confidence about its quality and the difficulties associated with collecting it led to great skepticism and poor adoption.  

In recent years, these issues have been addressed with the spread of technologies such as sensors that have made biometric data collection from patient-worn devices and other sources much easier and reliable. Patient-generated data is already playing an increasingly important role in clinical trials and remote patient monitoring and these trends will only accelerate, especially in the disease states outlined in the graph below. (These are areas where patient-generated data has shown great promise, including in mental health (e.g., depression and bipolar) during 2017.

 

3. Mobile Health = Healthcare

Mobile has become the default technology embedded into tools focused on patient engagement, compliance, clinical trials and other areas. Efforts to improve the vetting and review of mobile applications further drive mobile’s central role in health.

Mobile is one of our most mature and well-studied digital technologies. This has helped it become ubiquitous in health. In 2018 (and beyond), this technology will become so central that it be almost impossible to talk about global health without referencing mobile’s role.

In fact, in some areas, this has already happened. The charts below illustrate three areas where mobile is has been positioned as a central technology in late 2017: diabetes prevention, mental health and adherence/compliance.

 

4. The Blockchain Health Ecosystem Diversifies

With hospital executives, payers and others considering or deploying blockchain solutions, innovators recognize this technology has great potential in healthcare. Blockchain use cases diversify into anti-counterfeiting, health data marketplaces and other areas.

Thanks to the significant hype surrounding bitcoin and other crypto-currencies, blockchain has received significant attention. And, although many people confuse the two, blockchain is not bitcoin. Blockchain is simply another way to store many types of data — in a highly secure, immutable (write once, read only) fashion.  

Just like with relational databases and other data storage systems, many different application layers can be built on top of blockchain — and this is what we’ll see happen increasingly often in healthcare during 2018. 

Currently, as depicted in the Innovation Map below, blockchain technologies are enriching everything from mobile health to electronic medical records.

 

In 2018, we can expect to hear a lot more about blockchain’s role in health-focused artificial intelligence applications, precision medicine and genomics. The chart below illustrates how blockchain innovations have already become associated with these areas of global health.

 

 5. Empathetic Health Interfaces Mature

Advances in artificial intelligence, robotics, the Internet of Voice and related technologies accelerate the development of technologies that are more responsive, empathetic and human-like, which benefits elder care, mental health and other areas.

In my co-authored book, ePatient 2015 (released in 2013), we introduced a concept called empathetic interfaces. Driven by complex programs, we suggested empathetic interfaces would provide patients and others with responsive, intelligent companions that could guide mental health care and play a role in other areas of health.

In 2017, we saw empathetic interfaces make significant leaps forward, as chatbots, robotics and artificial intelligence have led to the creation of truly responsive interfaces that patients are beginning to trust and rely on.

One example of an empathetic interface is Catalia Health’s Mabu, an artificial intelligence and Internet of Voice-powered health companion that delivers patient education, enables data sharing with health providers and could help improve patient adherence and compliance.

In 2018, we will see empathetic interfaces expand across a range of areas, including depression, aging (providing companionship to older adults) and even rehabilitation. The chart below illustrates that these conditions are already closely associated with empathetic interfaces and additional applications of these innovations in these areas and beyond will be developed and introduced throughout 2018.

 

Source: http://hitconsultant.net/2017/12/05/digital-health-innovation-trends-2018/

Thanks to CVS, Aetna and Apple, virtual medicine is getting the marketing boost it needs by Mark Bertolini

104877873-IMG_8586a.530x298.jpg

Telemedicine, or virtual medical consults by phone or video, has been the "next big thing" in health care for more than a decade. But year after year, countless studies have found that telemedicine companies are held back by a lack of awareness among consumers.

Now, thanks to a marketing boost from behemoths like AppleAetnaand CVS, telemedicine might finally take off.

When pitching the benefits of a merger with CVS, Aetna's chief executive, Mark Bertolini, detailed how technology that monitors patients from home — like bluetooth-connected glucose meters coupled with apps for virtual providers to nudge patients when their glucose levels are off — is a key part of his strategy. In other words, telemedicine.

He described this strategy as an approach that will improve care andlower skyrocketing health costs for consumers by providing "a more holistic view of each individual."

Apple's COO, Jeff Williams, also advocated for virtual medicine last week, when detailing the company's plans for its new heart-health study. In an important move, Apple chose to work with one of the largest telemedicine start-ups, American Well, so that even those without easy access to a doctor's office can still get the help they need.

'It was a huge deal'

Apple and Aetna are signaling that the future of medicine involves a lot of monitoring of patients from home, rather than at the hospital or clinic.

And that's great news for the growing crop of venture-backed companies that offer virtual consultations, home-health monitoring and digital health apps. It's finally making people aware of some technology that's been around for years, which represents a more convenient alternative than a long drive to a medical clinic. It's also an affordable option, as most telemedicine visits are covered by insurance with a small copay.

"It was a huge deal," for us, said American Well's chairman and CEO, Ido Schoenberg, when asked about the Apple partnership.

Schoenberg said telemedicine companies have made big steps in overcoming other obstacles, including payment and state-by-state regulation.

But adoption remains a challenge. Hospitals and doctor's offices might increasingly start to offer virtual consults, he said, but it doesn't mean that consumers know they exist. And few people will peruse their insurance company or employer website to find out if it's a benefit.

"For so many people, this will be a new model of care presented to them for the first time," he said.

 

Source: https://www.cnbc.com/2017/12/04/cvs-aetna-and-apple-virtual-medicine-gets-a-marketing-boost.html